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The formation of neovessels is critical in the progression of solid tumors; hence, tumor 
angiogenesis is an attractive target for cancer therapy. A number of currently available anti-
vascular and anti-angiogenic pharmacologic drugs have been shown to induce objective clinical 
responses, however, the therapeutic effects of these drugs are only transient, with patients 
developing drug-refractory disease in most cases. Therefore, the development of alternative 
therapies that durably regulate the tumor vasculature remains an unmet clinical need. Due to the 
dysregulated angiogenesis within growing tumors, tumor blood vessels are morphologically and 
functionally aberrant. The cells that make up the tumor vasculature, including pericytes and 
vascular endothelial cells, exhibit genomic and proteomic profiles that are markedly different 
than their counterparts in normal tissues. These differences affect the functions of the tumor-
associated vascular cells, but they may also represent unique immunological targets for the 
development of interventional immunotherapies. In this thesis, I demonstrate that DLK1 and 
DLK2, which represent EGF-like protein antagonists of the Notch signaling pathway, are 
variably expressed in RENCA renal cell carcinoma-associated vascular pericytes.  Vaccines that 
coordinately target both of these antigens result in the activation and recruitment of DLK1- and 
DLK2-specific, as well as, tumor-specific CD8+ tumor-infiltrating lymphocytes (TIL). The pro-
inflammatory activity of vaccine-induced CD8+ TIL was associated with therapeutic 
reconditioning of the tumor stroma, and notably, the “normalization” of the tumor vasculature. 
Moreover, combination of immune checkpoint inhibitors (ICI) with the DLK1- and DLK2-
TUMOR BLOOD VESSEL-ASSOCIATED ANTIGENS AS TARGETS FOR CANCER 
IMMUNOTHERAPY 
Kellsye Paula L. Fabian, Ph.D. 
University of Pittsburgh, 2017
v 
targeted vaccine yielded a more effective therapy than either component modality, suggesting 
possible next-generation treatment options for patients with solid forms of cancer.  
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1.0  INTRODUCTION 
This chapter has been adapted from 
 
Fabian, K.P.L. and Storkus, W.J. Vascular remodeling, T cell trafficking and antitumor 
immunity. In: Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy, 
Donnadieu, E. (Ed.), Springer, New York, NY, pp. 51-76, 2016. 
and 
Fabian, K.P.L. and Storkus, W.J. (Immuno)therapeutic targeting of tumor-associated blood 
vessels. In: The Microenvironment in Cancer Progression and Cancer Therapy, Kalinski, P. 
(Ed.), Springer, New York, NY, in press, 2017. 
 
The immune system plays a major role in regulating the growth of cancer. In fact, the presence 
of tumor infiltrating lymphocytes (TILs), specifically CD8+ T cells and CD4+ T helper type 1 
(Th1) cells, has been associated with improved patient survival in a number of clinical studies 
involving various types of cancers, including melanoma, ovarian cancer, head and neck cancer, 
breast cancer, esophageal cancer, and colorectal cancer, to name just a few [1-5]. Type 1 TILs 
can limit tumor progression by directly killing tumor cells or by secreting chemokines and 
cytokines that mediate anti-tumor activities [6-8]. Therefore, the goal of cancer immunotherapy 
is to enhance the proliferation, migration, and activity of tumor-specific T cells.  
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Figure 1. Immunosuppressive populations in the TME.   
MDSCs: produce nitric oxide synthase, reactive oxygen species and arginase 1 that suppress T cell activity and 
proliferation and sequesters cysteine which is essential for T cell functions. Tregs: secrete immunosuppressive 
cytokines (IL10 and TGFβ) and function as sinks for other important homeostatic and antitumor cytokines, such as 
IL-7, IL-12, and IL-15. Tolerogenic dendritic cells (DCs): induce Tregs and fail to activate effector T cells. 
Macrophages (M2): secrete immunosuppressive factors (IL10, TGFβ, and vascular endothelial growth factor 
(VEGF)) and have impaired tumoricidal activity. (Adapted from Ref. [15]) 
 
However, circulating anti-tumor T cells face a hostile, immunosuppressive environment 
upon interaction with the tumor bed. Tumor and stromal cells could impede T cell recognition 
and functional activity by down-regulating MHC molecules [9], upregulating inhibitory 
receptors like programmed cell death protein ligand 1 (PD-L1) [10, 11] and secreting inhibitory 
factors such as transforming growth factor (TGF)β, interleukin (IL)-10 and prostaglandin E2 
[12]. The tumor stroma also contains large populations of immunosuppressive hematologic 
progeny, such as regulatory T cells (Tregs), myeloid derived suppressor cells (MDSCs) and M2-
like tumor-associated macrophages (TAMs) (Figure 1; [13, 14]). Despite such therapeutic 
Fibroblast
Pericyte
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concerns, one would be placing the proverbial “cart before the horse”, since in most cases, 
circulating T effector cells fail to gain entry into the tumor microenvironment (TME) because 
they are functionally and physically blocked by unique characteristics in the tumor-associated 
vasculature. Thus, the “tumor endothelial barrier” must be first broken, before worrying about 
regulatory mechanisms in place within the TME that serve to limit optimal anti-tumor T cell 
efficacy in vivo.  
1.1 ANGIOGENESIS AND CANCER 
1.1.1 The aberrant tumor vasculature 
Pathological angiogenesis is a hallmark of cancer [16]. Solid tumors, like normal tissues, require 
nutrients and oxygen as well as a mechanism to expel cellular waste and carbon dioxide. These 
requirements necessitate the formation of neovascular networks for tumor growth and 
maintenance. In adult normal tissues, angiogenesis is quiescent, occurring only under specific 
physiological conditions such as wound healing. Notably, in such cases, new vessels mature and 
stabilize rapidly because of the tightly- regulated balance of pro- and anti-angiogenic factors. 
During the onset of angiogenesis, the associations between vascular cells are relaxed and the 
extracellular matrix (ECM) dissolution is promoted by factors like vascular endothelial growth 
factor (VEGF) and angiotensin (Ang)-2 [17, 18]. The migration of vascular endothelial cells 
(VECs) is induced by VEGF-A, wherein subsets VECs with high levels of VEGF receptor 
(VEGFR), called the tip cells, direct the vascular outgrowth by sensing the gradient of the 
proangiogenic factor, ultimately infiltrating the avascular, hypoxic region of the tissue [19]. In 
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addition, VEGF also stimulates the tip cells of express the Notch ligand Delta-like protein (Dll)4. 
Dll4 then activates Notch receptors expressed on adjacent VECs, which causes the adjacent cells 
to downregulate their expression of VEGFR, becoming less responsive to the VEGF-mediated 
signals [20]. These neighboring VECs become stalk cells that proliferate and migrate in the 
direction of the tip cell, thus elongating the sprouting vessel [21]. During the resolution phase of 
angiogenesis, a new basement membrane is formed and pericytes are recruited to cover the 
vessel on its abluminal surface. Pericytes signal VECs to stop dividing and to form tight 
junctions and adherens junctions, in support of overall vascular integrity [21, 22]. 
On the other hand, in tumors, the production of pro-angiogenic factors is favored over 
anti-angiogenic factors, turning on the angiogenic switch. Tumorigenic conditions such as 
hypoxia [23], oncogene activation and tumor-suppressor mutation [24] contribute to the skewing 
of the balance towards the expression of pro-angiogenic factors. This imbalance leads to the 
sustained growth of tumor blood vessels that are very distinct from their normal counterparts. 
Tumor sprouting angiogenesis usually does not reach full resolution. Pericytes atypically remain 
only loosely-associated with the blood vessels [25] and the basement membrane is abnormally 
thick or thin [26]. Tumors also employ other mechanisms to instigate neo-vessel growth 
including: (1) vasculogenesis, in which endothelial progenitor cells are recruited from bone 
marrow or peripheral blood into the TME to form new blood vessels, (2) intussusception, in 
which VECs re-organize causing blood vessels to split and give rise to daughter vessels, (3) 
vessel co-option, in which tumor cells grow along existing blood vessels and (4) vasculogenic 
mimicry, in which tumor cells may de-differentiate into endothelial-like cells and form vascular 
tubes [27]. 
 
 5 
When compared to blood vessels in normal somatic tissues, the tumor vasculature is 
architecturally and functionally abnormal (Figure 2). The tumor vascular network is highly 
tortuous, disorganized and lacks the normal hierarchical arrangement of arterioles, capillaries 
and venules [28, 29]. The tumor vessels are also morphologically dilated and leaky with chaotic 
and variable blood flow, resulting in regions of tumor that are hypoxic and acidic [29]. In 
conjunction, the cellular components of the tumor blood vessels are also abnormal in their 
phenotype/function. VECs and pericytes exhibit altered gene expression profiles and elicit a 
defective basement membrane [26, 30, 31]. These alterations in expression of angiogenesis-
associated vascular components in progressor tumors are considered as strong targets for 
therapeutic intervention in patients with cancer. 
 
 
Figure 2. The tumor vasculature is architecturally and functionally abnormal. 
In healthy tissues (left panel), the vasculature is organized and has hierarchical architecture. The vascular endothelial 
cells (VEC) form a monolayer sheath that is covered with pericytes embedded in uniform basement membrane. In 
tumors (right panel), the vasculature is tortuous and disorganized. The endothelial sheath is porous, fenestrated, 
lacks pericyte coverage, and has uneven basement membrane. 
Basement((
membrane(
VEC(
Pericyte(
Normal' Tumor'
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1.1.2 Constituents of the tumor vasculature 
1.1.2.1 Vascular endothelial cells (VECs) 
VECs arise from hemangioblast precursors that are derived from the ventral floor of the 
dorsal aorta in the aorta-gonad-mesonephros region [32, 33]. During de novo organization of 
VECs into vessels (also known as vasculogenesis), newly formed VECs express growth factor 
receptors like VEGFR1 and VEGFR2 that allow VECs to proliferate, migrate and form tubular 
structures in response VEGF and fibroblast growth factor (FGF). Once the formed vessels 
mature, VECs down-regulate their expression of these growth factor receptors. In developing 
tumor blood vessels, however, VEGFR-1, VEGFR-2 and even VEGFR-3 (which is usually 
restricted to lymphatic vessels in adults) are re-activated and elevated in the VECs, allowing for 
the unrestricted proliferation and formation of blood vessels in the VEGF-rich TME [34-36]. 
Aside from growth factor receptors, tumor VECs also upregulate other genes that are typically 
not expressed on normal VECs [37, 38]. Most of these genes play a role in the angiogenic 
process, but some are induced by hypoxia or under conditions of abnormal blood flow [37, 39]. 
VECs are held together by cell-to-cell junctions to form a continuous monolayer of cells 
that lines the blood vessel. The normal endothelium acts as a selective barrier that tightly 
controls the exchange of substances between the blood and the surrounding tissue [33, 40]. 
Different membrane bound receptors present in the endothelium allow for the active transport of 
large molecules such as proteins, metabolites and hormones from blood into tissues [41]. The 
endothelial cells have junctional segments that are very similar to adherens and tight junctions in 
epithelial cells. These tight junctions are localized in the apical regions to seal the clefts between 
cells in the luminal surface, therefore, functionally restricting para-cellular permeability. On the 
other hand, adherens junctions occupy basal positions and function to limit para-cellular 
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permeability, as well as, to control vessel morphogenesis and stability [42-44]. The adherens and 
tight junctions also transfer intracellular signals that mediate contact inhibition of cell growth, 
cell polarity and VEC-pericyte interaction and, hence, allow VECs to adapt quickly to evolving 
changes in their microenvironment, such as release of growth factors, angiogenic cues and 
inflammatory conditions [44, 45]. Gap junctions are also present between neighboring cohorts of 
endothelial cells [42]. 
The endothelium in tumors is structurally defective, composed of irregularly-shaped 
endothelial cells that have long, fragile cytoplasmic projections that sometimes extend across the 
vessel lumen [46] and is characterized by intercellular gaps between endothelial cells, 
transendothelial holes and endothelial fenestrae (pores) [47-49]. Increased production of VEGF 
in the TME leads to a dissolution of the VE-cadherins and alternate adherens junction 
complexes, disrupting VEC cell-to-cell interactions [50]. These abnormalities render tumor 
vessels unusually leaky and highly-permeable to plasma proteins, and even erythrocytes. The 
leakiness and uncontrolled extravasation of blood and plasma results in increased interstitial 
(fluid) pressure within the tumor lesion [51]. Structural abnormalities and high interstitial 
pressure contribute to irregular blood flow resulting in the uneven and impeded distribution of 
nutrients, oxygen, and (systemically-administered) chemotherapeutic drugs within tumors. This 
also leads to areas in the tumor that are highly-acidic and hypoxic. The leaky tumor vessel can 
also promote the traffic of tumor cells into the blood stream and the eventual formation of distal 
tumor metastases [47]. 
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1.1.2.2 Pericytes 
Pericytes and vascular smooth muscle cells (vSMCs), collectively called mural cells, 
cover and support the endothelial tubules to maintain vascular integrity. Pericytes are usually 
found as single cells or as a discontinuous single-cell layer around arterioles, capillaries, and 
post-capillary venules [52]. On the other hand, vSMCs are generally identified around arteries 
and veins as multiple concentric layers of cells to mediate vascular tone and contraction [52, 53]. 
However, the distinction between pericytes and vSMCs is not always clear-cut and it has been 
suggested that there is a continuum of phenotypes ranging from the canonical vSMCs to classical 
pericytes rather than two distinct lineages of mural cells [53]. 
Pericytes have a number of different developmental origins such that within a single 
region of a given blood vessel, one may identify pericytes that derived from multiple precursor 
populations [54]. Furthermore, no single consensus pericyte marker has been identified to date. 
As such, pericytes are typically identified using a combination of different characteristics 
including location (i.e. cells embedded in a basement membrane that is shared with the 
endothelium; [55]), in addition to morphology and gene/protein expression profile.   
During physiological angiogenesis, pericytes are recruited to the developing vessel via 
soluble factors such as platelet-derived growth factor (PDGF)β, sphingosine 1-phosphate (S1P), 
Ang-1 and TGF-β1. The recruited pericytes form tight connections with the underlying 
endothelial cells with one pericyte usually in coordinate contact with multiple endothelial cells. 
Such pericyte interactions are very important in maintaining the integrity of the endothelium, 
playing a central role in regulating endothelial proliferation, differentiation, contractility, tone, 
stability, and permeability [53, 56-60]. However, the pericyte-endothelial cell interaction is 
disturbed in the TME, with poor pericyte coverage usually observed in a large proportion of 
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tumor-associated blood vessels. Tumor pericytes have cytoplasmic processes that extend into the 
tumor tissue [25] and are loosely associated with the endothelium [22, 25]. This abnormal 
pericyte-endothelial cell association contributes to increased vascular permeability [47], which 
results in poor perfusion and hypoxia, and modified basement membrane [61]. Tumor-associated 
blood vessels are prone to hemorrhaging, and typically exhibit a disrupted basement membrane 
[61]. The pericyte coverage of the endothelium is also very variable, depending on the type of 
tumor. For example, islet carcinomas have dense pericyte coverage while glioblastomas have 
drastically reduced numbers of pericytes per unit of venule area [22]. Variable coverage can also 
occur within the same tumor [61]. Pericyte coverage is thought to help maintain and stabilize the 
tumor vessels [62], with naked endothelium seemingly more dependent on VEGF for VEC 
survival [63]. Moreover, the tumor-associated pericytes exhibit an altered marker/protein 
expression profile, making them attractive targets for therapeutic intervention. Indeed, in tumors 
that overexpress PDGF receptor (PDGFR)β (leading to densities of pericytes), blockade of 
PDGFRβ signaling results in the physical detachment of pericytes from VEC, in association with 
restricted tumor growth [64-66]. 
1.1.2.3 Fibroblasts 
Cancer-associated fibroblasts (CAFs) are spindle-shaped cells embedded within the ECM 
that originate from resident fibroblasts and bone marrow-derived mesenchymal precursors [67, 
68]. They are phenotypically and functionally distinct from normal fibroblasts and comprise a 
significant proportion of the population of tumor-associated  stromal cells [69]. 
Although technically not a component of blood vessels, CAFs still play a major role in 
angiogenesis by promoting tumor blood vessel formation, principally via their production of pro-
angiogenic factors. Although cancer cells themselves can secrete VEGF, the principal source of 
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VEGF in most TMEs are CAFs [70]. In cancers such as pancreatic cancer and breast cancer, 
CAFs produce stromal-derived factor (SDF)-1 or CXC-motif chemokine ligand (CXCL)12, 
which contributes to tumor vascularization by recruiting endothelial precursor cells from the 
bone marrow [71-73]. CAFs may also indirectly promote tumor angiogenesis by secreting 
chemokines like CXCL1 and CXCL2 that recruit pro-angiogenic macrophages and neutrophils 
into the TME [74]. Furthermore, CAFs release matrix metalloproteinases that degrade the ECM, 
thus spatially accommodating the growing blood vessel and, at the same time, releasing VEGF 
previously sequestered in the ECM [75]. 
1.1.2.4 Basement membrane 
The basement membrane (BM) is a complex of proteins, glycoproteins and 
proteoglycans. The BM is similar to the ECM but has a different density and is always in contact 
with cells [26, 76]. The general role of the BM is to serve as boundary between tissue 
compartments, provide structural support, and regulating local cell behavior [77]. 
The vascular basement membrane envelops the VECs and pericytes and is primarily 
composed of Type IV collagen, laminin, fibronectin and heparin sulfate proteoglycan [76]. The 
BM is integral in the initiation and resolution of angiogenesis, as it possesses both pro- and anti-
angiogenic activities. Quiescent endothelial cells are bound to BM, indicating that the primary 
signals from BM inhibit VEC proliferation [78]. During active angiogenesis, the BM is degraded 
leading to the detachment of VECs and pericytes and the release of sequestered growth factors. 
Pro-angiogenic factors induce VEC to produce and embed in a provisional matrix composed of 
vitronectin, fibronectin, type I collagen and thrombin. Cryptic domains of Type IV collagen in 
partially degraded BM and the provisional matrix provide proliferative cues to the VECs [76, 
79]. 
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Deposition of basement membrane is dependent on VEC-pericyte interaction and 
disrupting this interaction by blocking pericyte recruitment, for example, results in perturbed or 
reduced basement membrane deposition [80-82]. Therefore, the abnormalities in tumor basement 
membrane can be partially explained by the disrupted VEC-pericyte interaction in the tumor. It 
was previously believed that BM was absent in tumor vasculature. However, more recent studies 
show that BM is present and can even fully cover tumor vessels albeit in an abnormal manner. 
Tumor vascular BM has variable thickness and multiple layers, suggesting that the BM has 
undergone several rounds of remodeling. In addition, the tumor BM exhibits only loose 
association with VECs and pericytes, which is characteristic of degenerating or forming blood 
vessels [26]. 
1.1.3 Tumor vasculature in cancer progression 
Several landmark studies have shown that tumor blood vessels and the process of angiogenesis 
are necessary for tumor progression. When tumor cells were implanted in avascular tissues, 
tumor growth was inhibited and limited until sprouting vessels were able to access an existing 
blood supply [83, 84]. Since the importance of the tumor blood vasculature was demonstrated, 
numerous studies have shown that it not only supports tumor growth by delivering nutrients, it 
also promotes tumor cell survival, confers drug resistance, helps to limit immune system 
surveillance, aids in metastasis and promotes stemness (Figure 3). 
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Figure 3. Tumor-promoting mechanisms by the tumor vasculature. 
The tumor vasculature support growth and survival of tumor cells by releasing tumorigenic factors (ex.EGF, HGF), 
impeding drug delivery and entry of effector immune cell infiltration into the tumor bed, supporting 
immunoregulatory cells, promoting metastasis and providing a niche for cancer stem cells. 
1.1.3.1 Tumor vasculature supports tumor growth and survival 
The tumor vasculature actively supports tumor growth by secreting factors that promote 
tumor survival. For example, the CAFs in the TME produce epidermal growth factor (EGF), 
hepatocyte growth factor (HGF) and heregulin that promote tumor cell proliferation and vitality 
[85]. VECs in head and neck squamous cell carcinomas (HNSCC) overexpress the anti-apoptotic 
molecule Bcl-2, which induces the production of VEGF through STAT3 signaling [86]. VEC-
derived VEGF binds the VEGFR1 expressed by tumor cells, triggering the production of Bcl-2 
in the HNSCC cells and enhancing their survival.  IL-6, CXCL8, and EGF derived from VECs 
also activate STAT3, Akt, and extracellular signal-regulated kinase (ERK) in the tumor cells, 
enhancing tumor cell migration and preventing their apoptosis. Interruption of these signaling 
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cascades by silencing Bcl-2 or the factors secreted by the VECs leads to inhibited tumor growth 
[87]. 
1.1.3.2 The aberrant tumor-associated vasculature confers drug resistance 
The tumor vasculature intrinsically confers therapy resistance by impeding drug delivery 
into the tumor lesion. The structural aberrations of the vessels cause excessive leakiness that 
leads to abnormal plasma accumulation and retention. This results in heterogeneous blood flow 
and high-interstitial fluid pressure in tumor tissue, preventing uniform distribution of 
systemically-administered anti-cancer drugs. Indeed, the erratic blood flow in the tumor 
promotes the concentrated delivery of drugs to the perfused outer (cortical) regions of the tumor 
while delivery to the poorly-perfused medullary tumor regions requires efficient 
perfusion/diffusion [88]. Furthermore, extravasation of therapeutic drugs into the TME is 
dependent on fluid movement across the vessel wall, which is influenced by a pressure gradient 
between the vessels and the interstitial space. The high interstitial fluid pressure in the tumor 
disrupts the development of an optimal gradient, thus hindering drug delivery to the tumor core 
[89]. The tumor-associated vasculature may also actively prevent drug delivery by 
overexpressing efflux pumps that promote rapid drug removal/detoxification [90, 91]. 
1.1.3.3 The tumor-associated vasculature contributes to immune escape 
The abnormal tumor vasculature not only impedes drug delivery, it also obstructs anti-
cancer immune response by limiting entry of effector cells while simultaneously contributing to 
an immunosuppressive TME. The adaptive T cell response is critical to protective anti-tumor 
immunity and the endothelium plays an important role in regulating the trafficking of T cells and 
other leukocytes into peripheral (inflamed) tissues. In normal tissues, resting VECs express little 
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to no adhesion molecules on their luminal surface interfacing with the blood supply. However, 
during infection or under conditions of tissue injury, pro-inflammatory signals such as 
lipopolysaccharide (LPS), tumor necrosis factor (TNF)-α and IL-1β induce the expression of 
adhesion molecules to allow the extravasation of leukocytes from the blood stream [92, 93]. E-
selectin and P-selectin expressed on VECs bind to their ligands Sialyl LewisX and P-selectin 
glycoprotein ligand 1 on the activated T cells and other leukocytes [94, 95]. This binding event is 
a weak affinity interaction that induces the tethering and rolling of the T cells on the inflamed 
luminal endothelium. The inflamed endothelium also presents chemokines that induce cell 
surface integrins, such as lymphocyte function-associated antigen-1 (LFA-1) and very late 
antigen-4 (VLA-4) on rolling T cells, allowing these cells to spread and cluster. Immune cell-
expressed LFA-1 and VLA-4 bind strongly to intercellular adhesion molecule-1 (ICAM-1) and 
vascular adhesion molecule-1 (VCAM-1) on activated VECs, mediating the arrest of interactive 
T cells on the inflamed endothelium in advance of the subsequent chemokine-driven 
extravasation of T cells into adjacent tissue. Expression of ICAM-1 and VCAM-1 are down-
regulated by an overabundance of angiogenic factors and other VEC-produced proteins (i.e. 
Egfl7 aka VE-statin) in the TME [96], resulting in the reduced flux of rolling leukocytes and 
lower densities of adhering leukocytes in tumor-associated blood vessels [97].  
Most studies on leukocyte trafficking into tissues focus on VECs, however, a growing 
literature suggests that pericytes also play significant roles in the extravasation and activation of 
effector immune cells. During inflammation, pericytes upregulate adhesion molecules, 
chemokines and cytokines [98-101] and may also display characteristics that are usually 
associated with antigen-presenting cells [102, 103]. Innate immune cells, specifically 
neutrophils, have been observed to crawl on pericytes [104]. It was later demonstrated that the 
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pericyte-expressed molecule NG2 (aka chondroitin-sulfate glycoprotein-4; CSGP4) interacts 
with neutrophils and macrophages, instructing them to migrate into inflammatory tissue sites 
[100]. It is currently unknown whether pericytes provide the same homing signals to 
transmigrating adaptive immune cells in the TME. Moreover, a recent study indicates that 
pericytes have a direct role in tumor immune escape by inhibiting CD4 T cell activation and by 
promoting T cell anergy through Regulator of G-protein Signaling-5 (RGS-5)- and IL-6-
dependent pathways [105].  
1.1.3.4 The tumor-associated vasculature facilitates an immunosuppressive TME 
Poor blood perfusion in the tumor leads to hypoxia, which has been shown to promote an 
immunosuppressive TME. Hypoxia drives the differentiation of tumor-infiltrating myeloid cells 
into M2-like TAMs. These M2-like TAMs adapt to the hypoxic environment by expressing 
hypoxia inducible factor (HIF)-1. HIFs are transcription factors that are stabilized under hypoxic 
conditions and are responsible for the expression of factors that allow cells to survive in a low 
oxygen environment. M2-like TAMs express high levels of IL-10, arginase I (Arg1) and TGFβ, 
which are factors known to suppress protective type-1 T cell-mediated immunity, and VEGF, 
which exerts pro-angiogenic effects [13, 106]. Furthermore, M2-like TAMs preferentially 
localize within hypoxic regions and TAMs that are situated near functional blood vessels express 
lower levels of the aforementioned M2-associated immunosuppressive gene products [106]. 
Hypoxic conditions also promote tumor cells to produce immunosuppressive molecules that 
inhibit effector T cell and natural killer (NK) cell survival/function, while coordinately 
supporting the Tregs and MDSCs [107, 108]. Hypoxia decreases the survival and activity of T 
cells in the TME, partly through inhibition of IL-2 in a HIF-1-dependent manner [109, 
110].  HIF-1 also drives expression of FoxP3 associated with Treg differentiation [111]. 
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Interestingly, these immunosuppressive cells also have pro-angiogenic activities, indicating that 
there are mutually reinforcing interactions between these regulatory cells and the tumor 
vasculature (Figure 4; [112]). 
 
 
Figure 4. Reciprocal reinforcing interactions between tumor vasculature and regulatory cells. 
The tumor vasculature produces factors that recruit and support immunosuppressive cells. The immunosuppressive 
cells, in turn, promote tumor angiogenesis. 
1.1.3.5 The tumor-associated vasculature contributes to metastasis 
Metastasis is a multistep process that involves dissociation of tumor cells from the 
primary tumor mass, invasion of surrounding stroma, intravasation to the vasculature, survival in 
circulation, extravasation to a distal site and subsequent colonization of new organs [113]. The 
tumor vasculature is primarily involved in intravasation of tumor cells but can also contribute to 
other metastatic steps [114, 115]. 
Hypoxia, due to poor blood perfusion brought about by the structural abnormalities in the 
tumor-associated vasculature, is a contributing factor to the acquisition of malignant phenotype 
[116]. During hypoxic stress, HIF-1α together with TGFβ triggers epithelial-to-mesenchymal 
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transition (EMT) in tumor cells. EMT is the process wherein epithelial markers are down-
regulated and mesenchymal markers are up-regulated, leading to the dissociation of epithelial 
cell-to-cell interactions and the facilitation of cell motility and invasiveness [117].  
Invasion of surrounding stroma by tumor cells requires a remodeling of the ECM and the 
migration of cancer cells through it. CAFs lead the metastatic tumor cells and utilize protease- 
and force-mediated activities to remodel the ECM [118]. Specifically, fibroblasts implement 
RhoA and Rho-associated protein kinase 1 to remodel the ECM in an matrix metalloproteinase 
(MMP)14-dependent manner [119, 120]. Cancer cells then follow these CAF-instructed 
microtracks in a CDC42-dependent manner [119]. 
The lack of an intact basement membrane and the disorganized VEC and pericyte 
interactions make the tumor blood vessels more accessible to motile tumor cells, easing the 
intravasation process [121]. Studies have shown that a high prevalence of abluminal pericytes 
limits tumor metastasis [122, 123]. In some tumor models, deficient pericyte coverage of blood 
vessels, due to a deficiency in pericyte recruitment, can be associated with increased metastatic 
potential [124]. Conversely, tumor cell intravasation is decreased when pericyte coverage of 
blood vessels is high within the TME [125].  
Cancer cells actively disrupt tumor blood vessel cell interactions in order to facilitate the 
intravasation process. For example, breast cancer cells express MMP17 which disturbs blood 
vessel integrity, leading to enhanced tumor cell migration and intravasation [126, 127] Malignant 
cells also secrete TGFβ1, which causes endothelial junction retraction [128]. Some cancer cells 
also express Notch receptors that bind to Notch ligands displayed on VECs, assisting their 
transmigration through the endothelial junctions [129].  
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In a complementary manner VECs in the TME also express factors that assist cancer cell 
intravasation. Breast cancer-associated VECs express the enzyme A Disintegrin And 
Metalloproteinase (ADAM)12 that cleaves vascular endothelial cadherin (VE-cadherin) and 
TIE2, both of which are also expressed on VECs [130, 131]. VE-cadherin is a component of cell-
to-cell adherens junctions that maintains the integrity of the endothelium, hence the ADAM12-
induced shedding of this molecule promotes enhanced vascular instability/permeability [131]. 
TIE2 is the receptor for Ang1 and Ang1/TIE2 ligation is important for pericyte recruitment to 
nascent blood vessels. ADAM12-mediated disruption of this interaction contributes to vessel 
destabilization, which is a prerequisite for cancer cell intravasation [130]. 
1.1.3.6 The tumor-associated vasculature promotes cancer stemness 
Although the existence of cancer stem cells (CSC) remains a subject of active debate, 
some research suggests that within a tumor mass, a minority of cells retain the ability to give rise 
to all cell types found in the heterogeneous tumor lesion, much like a normal stem cell has the 
potential to differentiate into many different types of cells. CSCs usually localize in certain 
specialized areas in the TME. These niches, composed of cells and matrix components, promote 
the maintenance of CSCs via direct cell contacts and secreted factors [132]. In HNSCC and 
glioblastoma, such CSC niches are commonly located in close proximity to tumor blood vessels, 
defining a perivascular niche [133, 134]. In these cancers, tumor-associated VECs appear 
directly involved in the maintenance of the CSC population through the release of soluble factors 
that support CSC self-renewal [135-137].  
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1.2 TUMOR VASCULATURE REMODELING 
Methods to inhibit tumor angiogenesis and to normalize tumor blood vessels for improved 
immune cell recruitment infiltration and anti-tumor function will ultimately be needed to ensure 
the optimal success of immunotherapeutic intervention. Anti-angiogenic agents were originally 
developed to prune the excessive neo-vasculature in tumors in order to cut their supply of 
nutrients and oxygen, leading to disease regression [138]. This was based on the principle that 
tumors necessitate the formation of new blood vessels to meet their metabolic requirements, as 
well as, their need to expel metabolic waste. Indeed, vascular pruning using high concentrations 
of antiangiogenic drugs, caused tumor growth delay and necrosis. However, this effect was only 
temporary, and eventually, hypoxia was again increased in the TME leading to renewed tumor 
angiogenesis via drug-refractory pathways. High doses of antiangiogenic drugs have also been 
shown to increase tumor invasion and metastasis.  
One must also consider that the tumor vasculature is required for the delivery of 
systemically-delivered anti-cancer drugs into the TME. Excessive vascular pruning using 
antiangiogenic agents actually impedes the effective delivery of chemotherapeutic drugs and 
renders radiotherapy ineffective [139, 140].  
Hence, instead of using anti-angiogenic therapy to ablate the tumor vasculature, it might 
be more rational to utilize this approach to instead, normalize it. Optimal doses of anti-
angiogenic agents, in fact, prune immature vessel branches and remodel the remaining vessels 
into more normal architectures. The normalized vasculature is less-tortuous, more-organized and 
less-leaky. This phenotype potentially alleviates hypoxia and interstitial fluid pressure in the 
TME and, therefore, could improve chemotherapy delivery into the TME. Furthermore, the 
normalized vasculature improves the oxygenation of the tumor, which is important for the anti-
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cancer action(s) of radiotherapy. Importantly, vascular normalization boosts tumor infiltration by 
immune effector cells and at the same time recondition the TME to become more pro-
inflammatory as a consequence of decreased hypoxia [139, 140]. The normalized vasculature 
also acts as a barrier that prevents cancer cell shedding and intravasation, conditional steps for 
subsequent metastasis [141]. 
1.2.1 TNFα therapy targeting tumor blood vessels  
TNFα is a vasoactive inflammatory cytokine that has the ability to activate VECs and, hence, if 
applied to tumors, can potentiate T cell extravasation and infiltration [142]. TNFα therapeutic 
effects are dose-dependent and associated with VEC activation, increased vascular permeability, 
VEC apoptosis and hemorrhagic necrosis. To avoid the pathologic effects of high doses of 
systemic TNFα, low concentrations of the cytokine must be targeted specifically to the tumor 
vasculature. To achieve this, a Cys-Asn-Gly-Arg-Cys (NGR) sequence serving as a ligand for 
the CD13 isoform expressed in tumor neovasculature, was fused with TNFα to develop  tumor 
vascular–targeting version of TNFα [143]. Therapy using TNF-NGR resulted in transiently 
enhanced tumor blood vessel permeability, and the increased efficiency of chemotherapy drugs 
delivery into murine tumors, without the development of systemic toxicities usually observed for 
administration of native TNFα. Low doses of NGR-TNF also activated the endothelium as 
evidenced by VEC upregulated expression of VCAM-1 and ICAM-2, and by VEC release of 
MCP-1/CCL-2, MCP-3/CCL-7, MIP-2, oncostatin-M and stem cell factor (SCF), factors that 
serve to attract and activate T cells. This TNF-based therapy also resulted in the loosening of 
VE-cadherin in the adherens junctions of VECs such that it favors T cell extravasation. 
Furthermore, this regimen led to reduced hypoxia in the TME, alleviating the 
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immunosuppressive environment and supporting TIL proliferation and survival. When applied 
with cancer vaccines and adoptive cell transfer (ACT), TNF-NGR enhances the efficacy of these 
immunotherapeutic modalities in the absence of significant toxicity [144]. Moreover, in phase II 
trials in relapsed patients with ovarian cancer, the combination of NGR-TNF and doxorubicin 
improved progression-free survival and overall survival [145].  
1.2.2 Metronomic chemotherapy targeting tumor blood vessels 
Most chemotherapeutic agents damage the DNA or inhibit microtubule formation in order to 
selectively kill rapidly dividing cells, which includes neo-angiogenic endothelial cells. 
Conventionally, chemotherapeutic drugs are administered at the maximum tolerated dose (MTD) 
in single doses or short courses followed by prolonged breaks between each therapeutic cycle 
[146] The two- to three-week break between cycles is necessary to allow the patient to 
recuperate from adverse drug reactions but it also affords the tumor endothelial cells time to 
recover and to reestablish pro-angiogenic programming [147]. 
Metronomic chemotherapy, on the other hand, involves the administration of low doses 
of chemotherapeutic agents on a frequent or continuous schedule with no drug-free break 
periods. Metronomic chemotherapy has been shown to have anti-angiogenic effects in vivo. It 
selectively prevents the proliferation and migration of endothelial cells, while blocking their 
apoptosis. Metronomic chemotherapy also leads to production of thrombospondin-1 (an anti-
angiogenic factor) and reduces the content of bone marrow-derived endothelial cell precursors 
within the treated TME [147]. 
Metronomic chemotherapy has also been reported to exert immunomodulatory effects 
that favor anti-tumor response. Several pre-clinical and clinical studies have shown that 
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metronomic chemotherapy reduces Treg populations and suppresses Treg function. Such 
interventions have been shown to coordinately improve lymphocyte proliferation and memory T 
cell expansion [147, 148].  
In clinical trials, metronomic chemotherapy when applied as a single modality or in 
combination with other anti-cancer therapies has demonstrated clinical benefits in patients with 
advanced breast cancer, recurrent ovarian cancer, hormone-resistant prostate cancer, advanced 
multiple myeloma, recurrent non-Hodgkins lymphoma, recurrent malignant glioma and 
glioblastoma, metastatic or locally advanced neuroendocrine carcinoma, among others. Response 
to metronomic chemotherapy was observed to last for several months and was associated with 
increased patient overall survival and with progression free-survival [148]. Furthermore, the 
vascular normalizing and immunomodulatory effects of metronomic chemotherapy make it a 
potential adjuvant for immunotherapy-based approaches. Indeed, metronomic cyclophosphamide 
therapy in combination with prophylactic gene-based vaccine targeting mel3 has been reported to 
inhibit B16.mel3 tumor growth in mice when compared to monotherapy with cyclophosphamide 
or vaccination [149]. However, several clinical studies have suggested that metronomic 
chemotherapy does not significantly improve anti-tumor efficacy of immunotherapy, although a 
trend has been reported for improved overall survival and even increased antigen-specific CD8+ 
T cell responses in some cases [150].  
Metronomic chemotherapy is generally well-tolerated and, thus, has the potential to 
improve quality of life with minimal toxicity. However, prolonged metronomic chemotherapy 
can lead to the accumulation of anti-cancer drugs and to the subsequent development of 
secondary diseases [151]. Furthermore, resistance to metronomic chemotherapy could develop 
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through reduced vascular dependence, in which resistant tumor cells grow in hypoxic and 
malnourished environments without the formation of a neovasculature [147].  
1.2.3 Anti-VEGF therapies targeting tumor blood vessels 
VEGF is an important driver of angiogenesis and is overexpressed in the TME of many forms of 
cancer. Hence, targeting VEGF has been the focus of numerous studies designed to inhibit tumor 
angiogenesis (Figure 5). To date, two anti-VEGF agents have been approved by the US Food 
and Drug Administration (FDA) for use as anti-angiogenic therapies for cancer: bevacizumab 
(Avastin, Genetech), which is a humanized anti-VEGF-A monoclonal antibody [152] and 
aflibercept (Zaltrap, VEGF-Trap, Regeneron and Sanofi Aventis), which is a recombinant fusion 
protein consisting of the extracellular domains of VEGFR1 and VEGFR2 and the Fc portion of 
human IgG [153]. Both bevacizumab and aflibercept bind VEGF and prevent its binding to 
VEGFR. Treatment with these anti-VEGF agents inhibits VEC proliferation, reduces vessel 
permeability, lowers tumor blood vessel density, and inhibits tumor growth [154-157].  
In pre-clinical studies, anti-VEGF treatment pruned immature tumor vessel branches, 
with the surviving vessels exhibiting a normalized phenotype and the TME displaying enhanced 
blood flow/perfusion and reduced hypoxia. However, vascular normalization and, therefore, 
clinical benefit with anti-VEGF treatments is only transient, with treatment-refractory disease 
rapidly developing in most cases. Hence, anti-VEGF therapy is typically administered in 
combination with chemotherapy to effect greater rates of (somewhat more durable) clinical 
response [158, 159].  
Bevacizumab, in combination with chemotherapy, has been approved as a first- or 
second-line treatment for metastatic colorectal cancer, non-small cell lung cancer (NSCLC), and 
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metastatic renal cell carcinoma and, as a single-agent, second-line treatment option for patients 
with recurrent glioblastoma [160]. Aflibercept, also used in combination with chemotherapy, has 
been approved as a second-line treatment for metastatic colorectal carcinoma [153]. 
1.2.4 Tyrosine Kinase Inhibitors 
VEGF, FGF, PDGF, and other angiogenic factors signal through specific receptor tyrosine 
kinases (RTKs). In general, RTKs consist of an extracellular ligand-binding region, a 
transmembrane helix, and a cytoplasmic tyrosine kinase domain. Activation of pro-angiogenic 
pathway begins with the binding of an angiogenic factor to its cognate RTK and the 
dimerization/oligomerization of the receptor. Assembly of the RTK complex induces a receptor 
molecule to phosphorylate one or more tyrosines in the adjacent receptor. The phosphorylated 
receptor then serves as a docking and activation site for other signaling proteins [161]. Tyrosine 
kinase inhibitors (TKIs) are small molecules that inhibit downstream signaling of RTKs by 
competing with ATP binding to the catalytic domain of tyrosine kinase [162]. 
Several TKIs targeting angiogenesis-related RTKs have been developed as anti-cancer 
treatment (Figure 5). Sunitinib (SU11248, Sutent, Pfizer), sorafenib (BAY43-9006, Nexavar, 
Bayer, Inc.), pazopanib (GW786034, Votrient, GlaxoSmithKline), and axitinib (Inlyta, AG-
013736, Pfizer) target VEGFRs and some of these TKIs also bind PDGFRs, stem cell factor 
receptor (c-Kit), Flt3 and other RTKs [163-166]. In vitro assays using human umbilical vein 
endothelial cells (HUVECs) demonstrated that sunitinib, sorafenib, pazopanib and axitinib 
inhibit downstream VEGFR signaling, leading to decreased proliferation, survival, migration and 
capillary tube formation of HUVECs [167-170]. In vivo, these TKIs normalize the tumor-
associated vasculature by suppressing angiogenesis and decreasing microvessel density. The 
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anti-angiogenic effects of these TKIs have been associated with tumor growth inhibition in a 
range of murine xenograft models [164, 168, 171-173]. 
 
Figure 5. Therapies targeting the tumor vasculature. 
a) Anti-VEGF therapies such as monoclonal antibodies and recombinant fusion proteins sequester the angiogenic 
factor VEGF. b) TKIs block downstream receptor signaling of an array of angiogenic pathways. c) TBVA-targeted 
immunotherapies promote TBVA-specific T cells that eliminate abnormal blood vessel cells and promote vascular 
normalization. When applied in combination with other anti-cancer modalities, tumor blood vessel-targeting 
therapies have been shown to improve delivery and efficacy of chemotherapy and cancer vaccines. 
 
Although developed as an anti-angiogenic drug, several pre-clinical studies have shown 
that sunitinib also has the capacity to reverse immune dysfunction in the TME. In MCA-26 colon 
and LLC1-Lewis lung carcinomas, treatment with sunitinib led to a reduction in 
immunosuppressive MDSCs and Tregs, while coordinately promoting CD8+ and CD4+ effector 
T cell infiltration into the TME. Type-2 immune responses were also blocked as suggested by the 
decrease in expression of IL-10 and TGFβ. Furthermore, sunitinib treatment decreased PD-L1 
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expression on MDSCs and DCs, and CTLA-4 and PD-1 expression in CD8+ and CD4+ T cells 
[174]. Similarly, sunitinib treatment also restored normal T cell function and suppressed MDSCs 
in the spleens of mice bearing B16, RENCA, CT26 and 4T1 tumors [175, 176]. Clinical results 
for sunitinib have provided concordant results. After one cycle of sunitinib treatment, the number 
of IFN−γ−producing (type-1) T cells increased, while IL-4-producing type-2 T cells were 
reduced in patients with renal cell carcinoma (RCC; [177]). Although no significant reduction in 
Treg cell frequency was observed in patient peripheral blood, there was an inverse correlation 
noted between increased type-1 T cell responses and decreased Treg levels in PBMC after 
sunitinib treatment. On the other hand, others have reported that sunitinib might have a negative 
impact on immune cells numbers/function. Sunitinib has been shown to inhibit T cell 
proliferation and to down-regulate expression of the activation markers CD25 and CD69 on in 
vitro (mitogen)-activated T cells isolated from healthy volunteers and cancer patients [178]. High 
doses of sunitinib have also been reported to block IL-12 production from DCs matured in vitro 
with IFN-α, TNF-α and poly I:C [179]. These data suggest that the dose and schedule of TKIs, 
such as sunitinib, must be carefully regulated based on possible (high-dose, chronic) immune-
toxicities.  
 
Anti-angiogenic TKIs have been FDA-approved as first-line or second-line treatment for 
different malignancies. Sunitinib is currently being administered as first-line therapy for patients 
with RCC and unresectable pancreatic neuroendocrine tumors (PNET). It is also approved as 
second-line therapy for patients with gastrointestinal stromal tumors (GIST) [180, 181]. 
Sunitinib is effective in inducing objective clinical responses patients with small cell lung 
carcinoma (SCLC), breast cancer, thyroid cancer and chondrosarcoma [180]. Sorafenib has been 
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approved as a therapeutic agent for advanced RCC, unresectable HCC, and recurrent or 
metastatic differentiated thyroid carcinoma [182, 183]. Pazopanib, on the other hand, has been 
approved for the treatment of patients with RCC or soft tissue sarcoma after standard-of-care 
chemotherapy [184, 185]. Axitinib has been approved as a second-line treatment option for 
patients with RCC [163].  
1.2.5 Tumor Blood Vessel-Associated Antigens (TBVA)-Targeted Vaccines 
The FDA approval of the first therapeutic cancer vaccine, sipuleucel-T (Provenge, 
Dendreon), has confirmed that antigen-specific vaccines can elicit the immune system to attack 
tumor cells in the clinical setting [186]. Sipuleucel-T is a treatment option for castration-resistant 
prostate cancer, targeting prostate acid phosphatase expressed on cancer cells. Tumor blood 
vessel cells are also attractive targets for active, specific immunotherapy, and hypothetically, 
have several advantages over cancer cells as targets. Cellular stressors in the TME cause unique 
epigenetic programing, resulting in unique phenotypes that allow for differential recognition of 
tumor stromal cells, including VECs and pericytes, from their normal counterparts by the 
adaptive immune response [30, 187, 188]. These tumor blood vessel-associated (TBVA) antigens 
may be targeted immunologically via active, specific vaccination to promote the activation of T 
effector cells that can selectively target abnormal tumor blood vessel cells, leading to the 
potential  normalization of the tumor-associated vasculature (Figure 5). VECs and pericytes are 
also strategically more visible to immune surveillance being highly-accessible to circulating 
immune effector cells in the blood. Lastly, VECs and pericytes are more genetically stable than 
tumor cells and, hence, less prone to adaptive mechanisms associated with immune escape. 
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Early TBVA-based vaccines targeted VEGFRs, which are highly expressed on the 
surface of tumor VECs in the neovasculature. In murine tumor models, peptide-based and gene-
based VEGFR1- and VEGFR2-targeted vaccines elicited antigen-specific CD8+ T cell responses 
in association with inhibited tumor angiogenesis and slowed disease progression [189-191]. The 
success of VEGFR-targeted vaccines in pre-clinical models drove the development of 
elpamotide, a vaccine against human VEGFR2 containing the HLA-A24-presented peptide 
epitope RFVPDGNRI [191, 192]. Phase I trials of elpamotide (as a single agent or in 
combination with other peptide vaccines and/or chemotherapy) demonstrated safety of the 
treatment and, to some degree, the ability of the approach to induce T cell immune responses 
associated with reduced angiogenesis in patients with pancreatic cancer, colorectal cancer or 
NSCLC [193-196]. However, in a Phase II/III clinical trial, elpamotide when used in 
combination with the chemotherapeutic agent gemcitabine, did not improve the overall survival 
of patients with advanced-stage pancreatic cancer [192]. 
Other TBVA that may not be directly involved in angiogenic pathways may also be 
targeted for use in tumor immunotherapies. Vaccination of HLA-A2 (HHD) transgenic mice 
bearing HLA-A2neg B16 melanoma or MC38 colon carcinoma with dendritic-based (DC1)-based 
vaccines incorporating HLA-A2-restricted peptide epitopes derived from TBVAs such as delta-
like homologue 1 (DLK1), EphA2, hemoglobin-β (HBB), NG2, NRP-1, PDGFRβ, RGS5 and 
TEM1 were shown to be effective in providing protective and therapeutic anti-tumor immunity 
[197]. The vaccination strategy resulted in tumor infiltration by CD8+ T cells that differentially 
recognized tumor VECs and/or pericytes, in association with a reduction in blood vessel density 
in the TME. Gene-based vaccination against TEM1 (aka CD248) has also been used as a 
prophylactic or therapeutic strategy against CT26 (colon), TC1 (cervical), and LLC (lung) 
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carcinomas, with the vaccine resulting in CD3+ T cell-dependent tumor growth inhibition. These 
results suggest that TBVA-targeted vaccination can lead to vascular normalization within the 
TME as a prelude to the more effective delivery of chemotherapeutic agents and ACT in 
combination treatment approaches.  
1.2.6 Chimeric Antigen Receptor (CAR) T cells 
CAR T cells are genetically-engineered to express antigen-specific receptors that combine 
antibody-like recognition and T cell receptor activating functions [198]. CARs are composed of 
antigen-binding region, usually single-chain variable fragments from monoclonal antibodies, a 
transmembrane domain and an endodomain derived from the CD3 zeta co-receptor.  
Recent clinical studies on CAR T cells, the majority of which were designed to treat B 
cell malignancies, suggest great promise in the clinic [199]. Thus far, however, CAR T cells 
have displayed only limited effectiveness in solid tumors due to their inability to actively migrate 
and extravasate into the TME. As a consequence, TBVA-targeting CAR T cells are being 
developed to circumvent the need for penetration into the TME (or to potentially improve co-
transferred anti-tumor CAR T cells based on vascular normalization mechanisms). CAR T cells 
engineered to target echistatin, which binds to the αvβ3 integrin expressed on tumor VECs, have 
been shown to lyse αvβ3 integrin+ HUVECs in vitro [200]. Treatment of tumor-bearing mice 
with echistatin-reactive CAR T cells led to the destruction of tumor blood vessels and inhibition 
of tumor growth. Adoptive transfer of VEGFR-2 CAR T cells co-transduced with cDNA 
encoding IL-12p70 has also demonstrated anti-tumor efficacy in tumor-bearing mice and 
prolonged overall survival [201]. Interestingly, this approach also resulted in a treatment-
associated reduction in tumor-associated MDSC (as previously observed for the anti-angiogenic 
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action of TKI as described above). Despite such promising pre-clinical results, TBVA-targeted 
CAR T cells have yet to be administered to cancer patients in the clinical setting. 
1.2.7 Combination therapy: vascular normalizing agents and immunotherapy 
Improved understanding of the complexities of cancer heterogeneity, genetics and oncogenic 
signaling pathways associated with acquired resistance to single modality therapies has 
reinforced the need to develop combination/multi-modality immunotherapies in order to 
reproducibly achieve durable objective clinical responses in the cancer setting. As single 
modality approaches (cancer vaccines, immune checkpoint inhibitors, ACT, among others) have 
each demonstrated promising (sustained) therapeutic benefits in a minority of treated patients 
[202, 203]. Cancer vaccines are effective in eliciting anti-tumor immune response but one of the 
main limitations is the inefficient delivery of vaccine-induced T cells into the tumor lesion [204]. 
A number of studies have suggested that anti-angiogenic agents may be largely immune-
dependent in their anti-tumor action, with many suggesting their use as adjuvants for integration 
into cancer vaccine formulations. Anti-angiogenic agents normalize the vasculature, increase 
blood perfusion and improve delivery of chemotherapeutic drugs and immune effector cells in 
the tumor bed [205]. In addition, some anti-angiogenic agents also have the capacity to reduce 
hypoxia and immunosuppressive MDSC and T cell populations and to promote the upregulation 
of vascular adhesion molecules and chemokines that enhance T cell recruitment into the TME 
[204, 206]. Indeed, in murine melanoma models, specific vaccination combined with systemic 
delivery of TKIs axitinib, sunitinib or dasatinib has resulted in superior therapeutic benefit when 
compared to either vaccination alone or TKI treatment alone. Concurrent administration of a 
DC/peptide vaccine and TKI improved the overall survival of M05 melanoma-bearing mice and 
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was associated with the upregulated expression of VCAM-1 and CXC-motif chemokine receptor 
(CXCR)3 ligand chemokines in the tumor endothelium and robust type-1 T cell infiltration in the 
TME  [175, 206, 207]. In another study, treatment of MC38 colon carcinoma-bearing mice with 
the combination of sunitinib pre-conditioning followed by a CEA gene-based vaccine was used 
treat mice, resulting in increased tumor infiltration by CEA-specific CD8+ T cells, decreased 
Treg and MDSC populations, reduced tumor volumes and prolonged survival [208]. 
Simultaneous administration of sunitinib and the vaccine, or administration of vaccine prior to 
sunitinib, however, did not did not result in improved survival [208, 209]. In a phase III clinical 
trial, the combination of a poxvirus-based vaccine encoding the tumor antigen 5T4 (TroVax) 
followed by administration of sunitinib was evaluated in renal cancer patients, with no benefit 
for the combined protocol versus sunitinib monotherapy observed [210]. These translational and 
clinical data strongly suggest that treatment schedule is likely critical to the success of such 
combination therapies. The temporal interval wherein the anti-angiogenic agents (TKIs, TBVA-
based vaccines, others) normalize the tumor vasculature and decrease immunosuppressive cell 
populations in the TME in advance of the arrival of vaccine-induced or ACT anti-tumor T cells 
must be determined in order to optimize the clinical benefits of such combination vaccines. This 
is further complicated by the effective window during which the adjuvant qualities of anti-
angiogenic inhibitors impact the TME, in the absence of off-target toxicities (including some 
manifest in immune cell populations). Hence, biomarkers to predict the efficacy of anti-
angiogenic drugs (i.e. increased systemic levels of CXCR3 ligand chemokines, reduced levels of 
CXCL12, etc.) or techniques to monitor blood perfusion in patients in a non-invasive manner 
must be developed to define an optimal combination schedule based on vascular normalization 
criteria [140, 211, 212]. 
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1.3 NOTCH 
1.3.1 Notch signaling and cancer 
The Notch signaling pathway is a highly evolutionarily conserved pathway that is involved in a 
myriad of cellular functions in invertebrates and vertebrates. During embryonic development, 
Notch signaling is vital in the maintenance of stem cell populations, determination of cell fate 
decision, and the regulation of proliferation and apoptosis. It is also associated with postnatal 
hematopoiesis, neural stem cell survival, immune regulation, and vascular development [213]. In 
mammalian systems, there are four known Notch receptors (Notch1, Notch2, Notch3, and 
Notch4) that contain 29-36 EGF repeats, of which EGF repeats 11-12 are essential for ligand 
binding and EGF repeat 8 dictates ligand specificity. Canonical Notch ligands (Jagged1, 
Jagged2, Dll1, Dll3, and Dll4) contain an amino-terminal Notch ligand motif, which (except for 
Dll3) is followed by a DSL (Delta-Serrate, LAG-2) protein domain and a DOS (Delta and OSM-
11) domain [214]. Archetypally, Notch signaling involves two distinct adjacent cells – the 
signal-sending cell, which presents the ligand and the signal-receiving cell, which express the 
Notch receptor. The pathway is activated when the DSL domain of the ligand physically 
interacts with the EGF repeats of the Notch receptor on a neighboring cell (Figure 6).  This 
interaction leads to the sequential cleavage of the Notch receptor: first, at the extracellular 
juxtamembrane region by (ADAM)10/17 metalloproteases and then within the intramembrane 
region by γ-secretase. The concerted catalytic action of ADAM10/17 and γ-secretase results in 
the release of the Notch intracellular domain (NICD), which then translocates into the nucleus 
where it associates with the DNA-binding transcription factor CSL (CBF-1, Su(H), LAG-1) and 
the transcriptional coactivator Mastermind. Targets of this transcription complex include the 
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HEY and HES transcription repressors and MYC transcription factor. The pathway is shut off 
when the NICD is degraded by the proteasome after its phosphorylation and (poly)ubiquitination 
[215-217]. 
 
 
Figure 6. The Notch signaling pathway. 
The Notch receptors (Notch 1-4) consist of an extracellular domain composed of multiple EGF-like repeats and an 
intracellular domain (NICD) that mediates downstream signaling. Upon binding of the extracellular domain to 
ligands (DLL and Jagged families), the Notch receptor is cleaved by ADAM and g-secretase. This proteolytic event 
releases the NICD, which subsequently translocates to the nucleus and binds to the transcription factor CSL. The 
NICD-CSL binding results in the dislocation of co-repressors (CoR) and recruitment of co-activators such as 
Mastermind (MAML). The heterocomplex then stimulates the transcription of Notch target genes such as members 
of the HES and HEY families. 
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The Notch signaling pathway has been implicated in a wide range of human diseases 
[218, 219]. The involvement of Notch signaling in cancer was first described in T cell acute 
lymphoblastic leukemia (T-ALL), where it acts as an oncogene that mediates the proliferation, 
growth, metabolism, and survival of T-ALL cells [220]. Since then, the tumor-promoting effects 
of Notch have been demonstrated in solid tumors such as breast cancer, colorectal cancer, non-
small cell lung carcinoma, medulloblastoma, and melanoma [221, 222], where aside from 
supporting the proliferation and survival of the tumor cells, Notch signaling also facilitates the 
invasion and migration of tumor cells [223] and the maintenance, and function of cancer stem 
cells [224]. 
Although Notch activation can be oncogenic, a growing body of evidence also shows that 
components of the Notch signaling pathway have tumor suppressive functions as well. In the 
skin, Notch activation induces differentiation and cell cycle arrest while the loss of NOTCH1 
results in increased cell proliferation in the basal epidermal layer, spontaneous basal cell 
carcinomas, and sensitization to chemically-induced skin carcinogenesis [225, 226]. Data also 
suggests that Notch activation suppresses tumorigenesis by inhibiting the Wnt and Sonic-
hedgehog signaling pathways [226]. This suggests that a crosstalk between Notch and other 
signaling pathways contributes to tumor inhibition in the skin. The Notch pathway has also been 
reported to act as a tumor suppressor in small cell lung cancer, chronic myelomonocytic 
leukemia, head and neck squamous cell carcinoma, gastrointestinal stromal cancer, endometrial 
cancer, and B cell malignancies [221, 222, 227, 228]. 
As described briefly earlier, Notch1-DLL4 signaling regulates angiogenesis and plays a 
vital role in the formation of an intact, functionally-mature vasculature under normal 
physiological conditions [20]. In tumors, DLL4 blockade results in the formation of a highly-
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branched vasculature that is dysfunctional [229, 230], however, there is also evidence  
suggesting that incomplete inhibition of Notch1-DLL4 signaling supports functional 
angiogenesis [231]. DLL4 inhibition leads to reduced tumor growth in certain models [229, 230] 
while prolonged DLL4 blockade also results in severe toxicities and the development of vascular 
tumors [232, 233]. Overall, these data indicate a delicate balance of Notch signaling in the 
various cell populations within the TME determines pro- versus anti- angiogenic behavior in 
vivo. 
The pleiotropic role of Notch signaling in diverse biological processes transmutes to its 
dual nature in cancer. In fact, in some cancer types such as pancreatic cancer, prostate cancer, 
and hepatocellular carcinoma, Notch can act as an oncogene or a tumor suppressor, depending on 
the cell type expressing the receptor, the strength of the signal or and/or the stage of the disease 
[234-236]. Hence, further investigation will be required to understand the contrasting roles of 
Notch activation within the TME in order to enable targeted interventions capable of rendering 
objective clinical responses in the cancer setting. 
1.3.2 DLK1 and DLK2 
Delta-like homolog 1 (DLK1, also known as Pref-1, FA-1 and pG2) is a protein that belongs to 
the EGF-like superfamily of proteins. The membrane-bound form of DLK1 contains six EGF-
like repeats, a tumor necrosis factor-a converting enzyme (TACE)-mediated cleavage site, a 
single transmembrane domain, and a cytoplasmic tail. [237]. The soluble form of DLK1 is 
released when ADAM17, a TACE, cleaves the protein [238]. Mammalian DLK1 resembles the 
structure of EGF-like repeats found in invertebrate homeotic proteins (such as Delta, Serrate, 
Notch and Lin-12) more closely than the mammalian EGF-like structures [237, 239]. However, 
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DLK1 lacks the DSL domain that is present at the N-terminus of canonical Notch ligands. 
Despite the absence of the DSL domain, DLK1 interacts with Notch1 and serves as an antagonist 
to DLL4- and Jagged1-mediated activation of Notch signaling [240, 241].  
DLK1 was first identified in the amniotic fluid (hence the alternative name fetal antigen-
1 or FA-1) and since then has been shown to be expressed in different embryonic tissues such as 
the pituitary gland, the adrenal gland, the mesenchymal regions of the developing vertebra, the 
tongue, the lung, and adipose tissues [237, 239, 242]. Differentiated adult tissues typically do not 
express DLK1 except in the case of some cells of the pancreas, testes, prostrate, and the ovaries. 
In some disease models, dysregulated overexpression of DLK1 is associated with the malignant 
transformation of adipocytes, cancer stemness maintenance in neuroblastomas and 
hepatocarcinomas, cell proliferation and migration in gliomas, and the faulty myogenic 
differentiation of mesenchymal cells in nephroblastoma (Wilm’s tumor) [243-248].  Conversely, 
exogenous expression of DLK1 in CAFs reduces tumor growth in a prostate cancer model [249]. 
Even with the widespread expression of DLK1 during embryogenesis, Dlk1 knockout 
mice manifest only mildly abnormal phenotype (growth retardation and abnormalities in the 
adipose tissue) and are able to reach adulthood and to reproduce [250], suggesting that another 
gene or set of genes are able to compensate for the absence of Dlk1. Another protein, DLK2 
(also known as EGFL9) that participates in adipogenesis has recently been reported to be highly 
homologous to DLK1 [251, 252]. DLK2 contains six EGF-like repeats, a transmembrane 
domain, and an intracellular region, which includes four putative SH3-binding sites that are 
absent in DLK1. Like DLK1, DLK2 acts as an inhibitor of Notch signaling and there is some 
evidence to suggest that these two proteins modulate each other’s expression. The role of DLK2 
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in cancer is largely unknown, with a single report suggesting the pro-oncogenic potential of 
overexpressed DLK1/2 proteins in SK-MEL2 melanoma cells [253]. 
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1.4 STATEMENT OF THE PROBLEM 
In the absence of neovascularization, tumors cannot exceed a certain size or metastasize 
to distal organs. At the same time, however, without an efficient (normalized) blood vessel 
network, delivery of anti-cancer agents and therapy-induced or -administered immune effector 
cells fails to occur. Hence, preventing abnormal angiogenesis while at the same remodeling the 
tumor vasculature to a more normal state is essential to the clinical success of a broad range of 
cancer treatments and immunotherapies.  However, existing strategies designed to normalize the 
tumor-associated vasculature, such as those that utilize pharmacologic chemotherapeutic agents, 
are only transiently effective, with drug-refractory disease inevitably developing. Therefore, 
alternative therapies targeting the dysfunctional tumor blood vasculature and capable of 
rendering a sustained state of vascular normalization are being actively pursued.   
This thesis describes the generation and assessment of therapeutic vaccines designed to 
target neoantigens expressed by tumor-associated pericytes, specifically the Notch antagonists 
DLK1 and DLK2. My findings suggest that vaccination against DLK1/DLK2 results in the 
activation of antigen-specific CD8+ T effector cells and to tumor vascular normalization, the 
recruitment of therapeutic immune cells into the TME, and to inhibition of tumor progression.. 
Furthermore, the anti-tumor efficacy of DLK1/DLK2-targeted vaccines may be improved by 
combination with current standard of care agents, such as anti-PD-L1. Overall, the results 
presented in this thesis provide a proof-of-principle that tumor blood vessel-associated antigens 
can targeted with immunotherapeutic interventions that may ultimately prove clinically-effective 
against a broad range of solid cancers. 
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2.1 ABSTRACT 
Tumor blood vessels are frequently inefficient in their design and function, leading to 
high interstitial fluid pressure, hypoxia, and acidosis in the TME, rendering tumors refractory to 
the delivery of chemotherapeutic agents and immune effector cells. Here we identified the Notch 
antagonist delta-like 1 homolog (DLK1) as a vascular pericyte-associated antigen expressed in 
RCC, but not in normal kidney tissues in mice and humans. Vaccination of mice bearing 
established RCC against DLK1 led to immune-mediated elimination of DLK1+ pericytes and to 
blood vessel normalization (i.e., decreased vascular permeability and intra-tumoral hypoxia) in 
the TME, in association with tumor growth suppression. After therapeutic vaccination, tumors 
displayed increased prevalence of activated VCAM1+CD31+ VECs and CXCL10, a Type-1 T 
cell recruiting chemokine, in concert with increased levels of Type-1 CD8+ TIL. Vaccination 
against DLK1 also yielded; i.) dramatic reductions in Jarid1B+, CD133+ and CD44+ (hypoxia-
responsive) stromal cell populations, ii.) enhanced tumor cell apoptosis and iii.) increased Notch 
signaling in the TME. Co-administration of a γ-secretase inhibitor that interferes with canonical 
Notch signaling resulted in the partial loss of therapeutic benefits associated with DLK1-based 
vaccination.  
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2.2 INTRODUCTION 
The vasculature of solid tumors is structurally and functionally “abnormal”, being 
composed of an irregular network of blood vessels characterized by aberrant coverage of 
endothelial tubes and a loosely-attached, largely immature population of mural cells (i.e. smooth 
muscle cells, pericytes) [25, 122]. In contrast to mature pericyte-VEC interactions found in 
normal tissues that orchestrates blood vessel integrity/stability [254], in tumors, this relationship 
is deranged leading to a high-degree of vascular permeability, high interstitial fluid pressure, 
hypoxia and acidosis [255].  
RCC is highly-vascularized and generally considered to represent an immunogenic form 
of cancer [256-258]. Current treatment options mediate only transient efficacy in a minority of 
RCC patients, with frequent development of progressive disease that is refractory to 
conventional chemo-/radio-therapy [259-262]. Vaccines targeting tumor-associated antigens 
have also thus far demonstrated only modest curative value [202]. The limited perfusion of 
tumor blood vessels likely contributes to the muted benefits of these treatment approaches by 
preventing the efficient delivery of chemotherapeutic agents and anti-tumor T cells into the TME 
[197, 263]. As a consequence, the development of novel therapies that can “normalize” the 
tumor vasculature (by coordinately improving blood vessel perfusion, reducing tumor hypoxia, 
and allowing for improved and sustained delivery of anti-cancer agents into the TME) remains a 
high-priority [139, 197, 264-266].  
To achieve the goal of tumor vascular normalization via immunization, we and others 
have recently advocated the use of vaccine formulations capable of promoting specific Type-1 
CD8+ T cell (aka Tc1) recognition of tumor-associated vascular cell antigens [197, 263, 266]. 
DLK1 is a member of the EGF-like family of proteins which includes Notch receptors and their 
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ligands [242, 243, 267] and serves as a functional inhibitor of Notch signaling. DLK1 has been 
reported to inhibit a broad range of Notch-dependent cell differentiation pathways [242]. In the 
cancer setting, the functional impact of DLK1 modulation cannot be intuitively assumed, since 
Notch activation has been reported to either promote or suppress tumor development/progression 
based on the contextual influences of DLK1 on the myriad cell populations located within the 
evolving TME [242, 243, 267].  
In this chapter, we investigated the therapeutic impact of active vaccination against 
DLK1 in a murine model of RCC (i.e., RENCA tumor cells transplanted s.c. into syngenic 
BALB/c mice), where the DLK1 antigen is preferentially expressed by blood vessel-associated 
pericytes in the progressively-growing TME. We show that DLK1 peptide- or gene-based 
vaccines are both immunogenic and therapeutic against established RCC, with treatment benefits 
linked to CD8+ T cell-mediated “normalization” of tumor-associated blood vessels (i.e., 
reduction in blood vessel numbers and extent of arborization, loss of hypoxia and reduced 
vascular permeability) (98, 182). Responder tumors were highly-infiltrated by CD8+ TIL that 
localized within the perivascular (pericyte-enriched) space. Residual pericytes lacked expression 
of DLK1 and were tightly-approximated to CD31+ VEC. Consistent with the vaccine-induced, 
immune-mediated eradication of tumor-associated DLK1 protein expression, increased Notch 
signaling was evidenced within the therapeutic TME. These results are consistent with the ability 
of DLK1-based vaccines to promote therapeutic CD8+ T cell-dependent vascular normalization 
in the RCC microenvironment, supporting the clinical translation of such approaches in the 
setting of RCC and other forms of solid cancer.  
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2.3 MATERIALS AND METHODS 
2.3.1 Mice  
Female 6-8 week old BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) were maintained 
in a pathogen-free animal facility, with all animal work performed in accordance with an 
IACUC-approved protocol.  
2.3.2 Tumor cells  
The mouse RCC line RENCA derived from a spontaneous renal cortical adenocarcinoma in 
BALB/cCr mice (CRL-2947; American Type Culture Collection, Manassas, VA) [268] was 
cultured as previously reported [266].  
2.3.3 Stromal cell isolation  
Human RCC tumor and adjacent (patient-matched) normal kidney specimens were obtained with 
written-consent under an IRB-approved protocol. Murine RCC tumors and tumor-uninvolved 
kidneys were harvested 21 days after s.c. injection of 106 RENCA cells into syngenic BALB/c 
recipient animals. VEC and pericytes were isolated as previously mentioned in Chapters 2 and 3 
with minor modifications [269]. Briefly, tissues were enzymaticaly digested into a single cell 
suspensions and, for human specimens, labeled with anti- human CD146 FITC (Serotec), anti-
human CD34 PE (DAKO), anti-human CD56 PE-Cy7 (Serotec), anti-human CD45 APC (BD-
Biosciences) and for murine specimens, labeled with anti-mouse CD34-FITC (eBioscience, San 
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Diego, CA), anti-mouse CD146-PE (BD-Biosciences, San Diego, CA), and anti-mouse CD45-
APC (BD-Biosciences) prior to flow sorting into pericyte (CD146+CD34negCD56negCD45neg) and 
VEC (CD146+CD34+CD56negCD45neg) populations.  
2.3.4 Real-time PCR  
Messenger RNA was isolated from pericytes and VEC using the RNeasy® Plus Micro kit 
(Qiagen, Valencia, CA) according to manufacturer’s instructions. cDNA was then generated 
using High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad, CA) and real-time PCR 
performed using Fast SYBR® Green Master Mix (Applied Biosystems) with primer pairs for 
human or mouse HPRT1 (Qiagen), human DLK1 (Applied Biosystems) or mouse DLK1 
(forward primer: TGTGACCCCCAGTATGGATT, reverse primer: 
CCAGGGGCAGTTACACACTT). Reactions were performed in duplicate in a 96-well reaction 
plate on a StepOnePlus real-time PCR thermocycler (Applied Biosystems) using cycling 
conditions of 95°C for 20 min., then 35 cycles of 95°C for 3 min. and 60°C for 30 min.  
2.3.5 In vitro generation of bone marrow-derived dendritic cells (DC) and DC.IL12  
DC were generated from bone marrow precursors isolated from the tibias/femurs of mice using 
in vitro cultures containing 1,000 U/ml recombinant murine granulocyte/macrophage colony-
stimulating factor and 1,000 U/ml rmIL-4 (both from Peprotech, Rocky Hill, NJ), as previously 
described [266]. The Ad.mIL-12p70 recombinant adenoviral vector was produced and provided 
by the University of Pittsburgh Cancer Institute's Vector Core Facility (a shared resource), as 
reported previously [266, 270]. Five million (day 5 cultured) DCs were infected at a multiplicity 
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of infection = 50 with Ad.mIL-12p70 or the control, empty vector Ad.ψ5. While control DC 
produced <62.5 pg IL-12p70/ml/48 hour/106 cells, DC.IL12 cells produced 1–10 ng IL-
12p70/ml/48 hour/106 cells. 
2.3.6 Synthetic peptides  
The H-2d class I-presented DLK1158-166 (CPPGFSGNF; presented by H-2Ld), DLK1161-169 
(GFSGNFCEI; presented by H-2Kd), DLK1259-270 (TILGVLTSLVVL; containing overlapping 
DLK1259-267 and DLK1262-270 sequences presented by H-2Kd) peptide were synthesized as 
previously described  [197].  
2.3.7 Recombinant lentiviral vector production  
Genes encoding mDLK1 and the reverse sequence of mRGS5 (as a negative control) were 
cloned into the pLenti6/V5 D-TOPO vector downstream of the CMV promoter using the 
Lentiviral Directional TOPO® Expression Kit (Invitrogen, Grand Island, NY). To determine 
insert presence in the plasmid, expression of the V5 tag was detected by immunofluorescence 
using an anti-V5 FITC antibody (Invitrogen) and by western blot using an anti-V5 HRP antibody 
(Invitrogen). In the initial production of the lentiviruses, 293FT cells (Invitrogen) were 
transfected with plasmid DNA pLenti-DLK1 (or pLenti-NEG) using ViraPower™ Packaging 
Mix (Invitrogen) combined with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. After 48 hours, lentivirus was collected and concentrated using a 
Fast-Trap Virus Purification and Concentration kit (Millipore). Lentiviral (lvDLK1 and lvNEG) 
titers, reported in transduction units (TU), were determined by quantitating blasticidin 
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(Invitrogen)-resistance in HT-1080 cells (kindly provided by Dr. Chuanyue Wu, University of 
Pittsburgh) according to the manufacturer’s instructions. Expanded lentiviral production was 
performed by the University of Pittsburgh Cancer Institute Lentiviral Vector Core Facility. 
Lentivirus quality was assessed by infecting HT-1080 cells for 24h and monitoring cells for 
coordinate V5 protein expression (western blot) and cell-surface expression of DLK1 (flow 
cytometry using an anti-DLK1-PE conjugated antibody; Adipogen, San Diego, CA). 
2.3.8 Animal therapy experiments  
BALB/c mice received s.c. injection of 106 RENCA tumor cells (right flank) on day 0. Six days 
later, the animals were randomized into cohorts of 5 mice with comparable mean tumor sizes. On 
days 7 and 14 after tumor implantation, mice were treated with 100 µl s.c. injections (left flank) 
of PBS, 106 DC.IL12 or 106 DC.IL12 that had been pre-pulsed for 2h at 37°C with an equimolar 
(10 µM) mixture of the DLK1158-166, DLK1161-169 and DLK1259-270 peptides. For lentivirus 
vaccination experiments, randomized BALB/c mice bearing established (day 10; right flank) s.c. 
RENCA tumors received a single left flank intradermal injection of lvDLK1 or negative control 
lvNEG at a dose of 4 x 104 or 2 x 105 TU in a total volume of 50 µl PBS. For all animal 
experiments, tumor size was assessed every 3 to 4 days and recorded in mm2, as determined by 
the product of orthogonal measurements taken using vernier calipers. Data are reported as mean 
tumor area ± SD. To determine the impact of canonical NOTCH signaling on vaccine efficacy, 
tumor-bearing animals vaccinated with lvDLK1 or lvNEG were injected i.p. with the g-secretase 
inhibitor DAPT (10 mg/kg/day in 50 ml DMSO (Sigma-Aldrich) on a 3 consecutive days 
(followed by 4 days without injections) per week schedule, for 2 weeks beginning on day 12 
post-tumor inoculation) or vehicle control (DMSO).  
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2.3.9 Evaluation of specific CD8+ T cell responses in vitro  
Spleens were harvested from three mice per group 7 days after the second DC injection. 
Splenocytes were then stimulated in vitro for 5 days with syngenic DC pulsed with an equimolar 
(10 µmol/l) mix of the three DLK1 peptides applied in the vaccine. Responder CD8+ T cells were 
then isolated using magnetic bead cell sorting (Miltenyi Biotec, Auburn, CA) and co-cultured 
with syngenic DC pulsed with individual DLK1 peptides for 72 hours, 37 °C and 5% CO2, at 
which time cell-free supernatants were analyzed for mIFN-γ content using a cytokine-specific 
ELISA (BD-Biosciences). 
2.3.10 Fluorescent imaging of tumors 
Tumor tissue samples were prepared and sectioned as previously reported [266]. Six micron 
tissue sections were analyzed for expression of CD31 (BD-Biosciences), VCAM1 (R&D 
Systems, Minneapolis, MN), CXCL10 (R&D Systems), NG2 (Millipore), DLK1 (Santa Cruz 
Biotechnology, Santa Cruz, CA), RGS5, Jarid1b (all from Abcam, Cambridge, MA), CD133 
(BD-Biosciences), CD44 (Abcam), and Hes1 (Millipore) by immunofluorescence microscopy, 
with wide field images collected with fixed illumination conditions using a cooled CCD camera 
(Olympus Magnafire; Olympus, Center Valley, PA). Using Metamorph software (Molecular 
Devices, Downingtown, PA), images were thresholded to delineate signal above background and 
individual structures measured as the integration of pixel number (total number of positive pixels 
in the structure above background) multiplied by the brightness of each pixel in gray scales. This 
product provides the integrated pixel intensity of positive structures and is reported as the mean 
integrated fluorescence intensity ± SD. For the analysis of activated VEC in the TME, cellular 
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identity was first defined using co-localization of specific markers (cells staining for both CD31 
and VCAM-1) using image overlay and manual counting. We found this method was essential to 
ensure accuracy in cell identification in tissue with complex morphologies. To perform the 
quantification images were overlaid with Metamorph software and co-localized structures that 
could be defined as cells were counted. For analysis of cellular apoptosis, tissue sections were 
labeled using TUNEL kit (Roche, Indianapolis, IN) as per the manufacturer's instructions, 
followed by incubation with secondary anti-streptavidin Cy3 antibody (Jackson 
Immunoresearch, West Grove, PA). Some sections were analyzed by confocal microscopy to 
generate 30 µm 3D reconstructions of images. For the vascular permeability imaging, animals 
received retro-orbital intravenous injections of FITC-labeled tomato lectin (Sigma-Aldrich) and 
red 20  nm FluoSpheres (Invitrogen), followed by cardiac perfusion of PBS and 4% 
paraformaldehyde. Tumors were then immediately resected and imaged by confocal microscopy 
to generate 17 µm 3D reconstructions. In all depicted tissue images, white ruler insets indicate 50 
µm (low magnification images) or 10 µm (high magnification images). 
2.3.11 Hemoglobin quantitation 
The amount of hemoglobin contained in tissues was quantitated using the Drabkin method 
[271] and reported as µg hemoglobin per mg wet weight of tissue. 
2.3.12 Measurement of tumor hypoxia using pimonidazole 
BALB/c mice bearing established (treated or untreated) day 21 s.c. RENCA tumors were 
injected i.p. with 60  mg/kg pimonidazole hydrochloride (Hypoxyprobe; HPI, Burlington, MA) 
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30 minutes before euthanasia and tumor harvest and 6 µm tissue sections prepared and analyzed 
by immunohistochemistry as previously reported [266]. 
2.3.13 RNA purification and reverse transcription-PCR array 
Total RNA was isolated from bulk single-cell suspensions of day 21 tumors harvested from 
lvNEG- or lvDLK1-treated mice using Trizol reagents (Invitrogen). Total RNA was further 
purified using the RNeasy Plus Mini Kit (Qiagen) including the gDNA Eliminator spin column. 
The purity and quantity of the total RNA was assessed using Nanodrop ND-1000 (CelBio SpA, 
Milan, Italy). Total RNA (1 µg) was reversed transcribed into cDNA using the RT2 First Strand 
Kit (Qiagen) and the cDNA added to RT2 SYBR Green ROX qPCR Mastermix (Qiagen) and 
used for quantitative PCR using the RT2 Profiler PCR Array (96-well) for Mouse Notch 
Signaling Pathway (Qiagen) all according to the manufacturer's instructions. Reactions were 
performed on a StepOnePlusTM Real-Time PCR thermocycler (Applied Biosystems) using the 
recommended cycling conditions. All mRNA expression levels were normalized to the 
expression of GAPDH. 
2.3.14 Statistical analysis 
Comparisons between groups were performed using a two-tailed Student's t-test or one-way 
analysis of variance with Tukey's post-hoc analysis, as indicated. All data were analyzed using 
SigmaStat software, version 3.5 (Systat Software, Chicago, IL). Differences between groups with 
a P value <0.05 were considered significant. 
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2.4 RESULTS 
2.4.1 RCC-associated pericytes differentially express the DLK1 antigen 
In a previous report [197], we identified several melanoma-associated vascular antigens, 
including DLK1, which may represent promising therapeutic vaccine targets. Before assessing 
the therapeutic potential of DLK1 peptide- and gene-based vaccines in the setting of RCC, we 
first investigated the pattern of DLK1 expression in the TME and tumor uninvolved kidneys of 
BALB/c mice harboring established syngenic RENCA (an RCC line established from a 
spontaneously arising renal adenocarcinoma of BALB/c origin) [268] tumors. After enzymatic 
digestion of tissues, tumor- and kidney-derived pericytes and VEC were isolated via flow sorting 
from single-cell suspensions (Figure 7a) and their extracted mRNA (along with mRNA from the 
cultured RENCA cell line) was analyzed by real-time PCR for DLK1 (and housekeeping control 
HPRT1) transcript content (Figure 7b). We observed that pericytes sorted from RCC tumors 
were uniquely enriched for DLK1 transcripts (Figure 7b) when compared with normal kidney 
vascular cells or RENCA tumor cells, suggesting that DLK1 may represent a general tumor 
pericyte-associated antigen. Immunofluorescence microscopy performed on day 21 RENCA 
tumor sections confirmed that DLK1 protein was coexpressed by NG2+ (a general marker of 
pericytes in both normal and tumor tissue; [272]) pericytes that were closely approximated to 
CD31+ VEC in situ (Figure 7c). 
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Figure 7. DLK1 is differentially expressed by RENCA tumor-associated pericytes. 
The spontaneously arising renal cortical adenocarcinoma RENCA (106 tumor cells) was injected s.c. into female 
BALB/c mice and allowed to progress for 21 days after which animals were euthanized and tumors and normal 
kidneys harvested. (a) Tissues were processed into single-cell suspensions and sorted by flow cytometry based on 
forward versus side scatter profiles, DAPI exclusion (to reject dead cells), a CD45neg phenotype (i.e., non-
leukocytic), and then selectively into CD146+CD34neg pericytes and CD146+CD34+ VEC populations based on 
published assignments of these cell lineage-restricted phenotypes [273, 274]. (b) mRNA was then isolated from 
flow-sorted pericytes and VEC, and analyzed for DLK1 transcript expression by real-time PCR. Relative mRNA 
expression was normalized to housekeeping HPRT1 mRNA expression. (c) Day 21 RENCA tumor tissue sections 
were analyzed for expression of CD31 (blue), NG2 (green), and DLK1 (red) by immunofluorescence microscopy. 
Metamorph quantitation (Materials and Methods) was performed on 10 high power field (HPF) of the fluorescent 
images, with 28.1  ±  4.4% of tumor-associated NG2+ pericytes coexpressing the DLK1 marker. The analysis also 
revealed that the majority (i.e., 58.9  ±  7.6%) of DLK1+ cells coexpressed the NG2 marker within the TME. All data 
are representative of three independent experiments performed. DAPI, 4′,6-diamidino-2-phenylindole; FSC, forward 
scatter; SSC, side scatter; TME, tumor microenvironment; VEC, vascular endothelial cell. 
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2.4.2 Treatment of RENCA tumor-bearing mice with a DLK1 peptide-based vaccine is 
therapeutic and associated with specific type-1 CD8+ T cell (Tc1) activation and 
recruitment into the TME.  
We have previously demonstrated that vaccine formulations composed of interleukin-12 
(IL-12) gene-modified dendritic cells (DCs) (i.e., DC.IL12) pulsed with major histocompatibility 
complex class I-presented peptides promote robust CD4+ T helper cell-independent priming of 
antigen-specific CD8+ T cells in vivo [197, 275]. Using this approach, we analyzed the impact of 
treating BALB/c mice bearing established s.c. RENCA tumors with a DLK1 peptide (a pooled 
equimolar mixture of the DLK1158–166, DLK1161–169, and DLK1259–270 peptides)-based vaccine. 
As depicted in Figure 8a, mice treated with the DLK1 peptide-based vaccine, but not a control 
vaccine (i.e., DC.IL12, no peptide) or phosphate-buffered saline (PBS), exhibited a significant 
reduction in the growth of RENCA tumors (Figure 8a; P < 0.05 (analysis of variance) on days 
>13). On day 21 (i.e., 7 days after the booster immunization), CD8+ splenocytes were isolated 
and analyzed for secretion of interferon-γ (IFN-γ) in response to stimulation with specific DLK1 
peptides presented by syngeneic DC in vitro. We noted elevated levels of IFN-γ secretion from 
CD8+ T cells isolated from mice treated with the DC.IL12 + DLK1 peptide vaccine (versus mice 
treated with DC.IL12 only or PBS) after stimulation with individual DLK1 peptides, indicating 
that the vaccine induced poly-specific, anti-DLK1 CD8+ T cell responses in vivo (Figure 8b). 
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Figure 8. DC/DLK1 peptide-based vaccines are both immunogenic and therapeutic in the murine RENCA 
model of RCC. 
BALB/c mice were inoculated with RENCA tumor cells s.c. on the right flank on day 0. (a) After randomizing for 
similar mean tumor size per treatment cohort (n = 5), mice were injected s.c. on their left flank on days 7 and 14 
(post-tumor inoculation) with PBS, 106 DC.IL12 or 106 DC.IL12 pre-pulsed with equimolar mix (10 µmol/l each) of 
the three synthetic DLK1 peptides. Tumor growth (mean ± SD) was then monitored over time. (b) On day 21 post-
tumor inoculation, splenic CD8+ T cells were isolated from each cohort and co-cultured with syngenic DC pre-
pulsed with individual DLK1 peptides for 24 hours, at which time, IFN-γ ELISA were performed on the harvested 
cell-free supernatants. (c,d) Day 21 tumors were fixed, sectioned and analyzed by immunofluorescence microscopy; 
CD31 (green in c,d), CXCL10 (red in c), VCAM1 (red in d). The percentage of VCAM1 co-localization with CD31 
is depicted as a yellow signal in d and was quantitated using Metamorph software as described in Materials and 
Methods. Histograms to the right of images reflect mean fluorescence intensity quantitation of the indicated markers 
(±SD) from three independent fields per slide as described in Materials and Methods. Data are representative of 
 54 
three independent experiments performed. *P < 0.05 versus control treatments (analysis of variance). DC, dendritic 
cell; IFN, interferon; PBS, phosphate-buffered saline; RCC, renal cell carcinoma. 
 
Since therapeutic type-1 CD8+ T cells preferentially express a VLA-4+ CXCR3+ 
phenotype [175, 276], we next determined whether specific vaccination resulted in the altered 
expression of VLA-4 and CXCR3 ligands, VCAM-1 and CXCL10, respectively in the TME. A 
coordinate immunofluorescence microscopy analysis of the TME after DLK1 peptide-based 
vaccination versus control treatment revealed fewer CD31+ tumor blood vessels (Figure 8c), and 
these vessels contained VEC enriched in the activated VCAM1+ phenotype (Figure 8d). We also 
observed that these same tumors contained elevated levels of CXCL10/IP-10 chemokine protein 
expression versus control tumors (Figure 8c), suggesting that the DLK1-based vaccination 
induces a proinflammatory TME that is competent to recruit type-1 T effector cells. 
2.4.3 Vaccination with a recombinant lentivirus encoding murine DLK1 cDNA is 
therapeutic in the RENCA model of RCC 
Clinical trials implementing synthetic tumor peptide-based vaccines have needed to restrict 
patient accrual to those individuals expressing relevant human leukocyte antigen class I (peptide-
presenting) allotypes. To develop a more universal immunization platform, we next engineered a 
genetic vaccine that would theoretically allow for virally transduced host antigen-presenting cells 
to cross-prime a more comprehensive anti-DLK1 T effector cell repertoire. Given the reported 
superiority of lentiviral-based vaccines to promote prolonged antigen-specific CD8+ T cell 
responses after a single administration in vivo [277], we first constructed a recombinant 
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lentivirus encoding full-length murine DLK1 (lvDLK1) and a negative control virus (lvNEG; 
Figure 9). 
 
 
Figure 9. Production of recombinant lvDLK1 and control lvNEG lentiviruses. 
In (a), a schematic diagram is provided for lvDLK1. pRSV/5′LTR, RSV LTR and HIV LTR chimeric promoter; 
RRE, Rev response element sequences; CMVp, CMV promoter used to drive transgene expression; whole mouse 
DLK1 gene with V5 reporter tag; SV40p-Blasticidin, SV40 virus promoter used to drive selection marker blasticidin 
gene expression; ΔU3/HIV 3′LTR, promoter deleted in U3 region so that the lvv become selfinactivated; TOPO 
cloning sites also indicated. 293T cells were transfected with plasmid DNA pLenti-DLK1 (or pLenti-NEG) and 
analyzed for V5 protein expression by (b) immunofluorescence and (c) western blot. HT-1080 cells were infected 
with lentivirus and analyzed for (c) V5 protein expression by western blot and (d) DLK1 protein expression by flow 
cytometry. (e) Production of a live functional virus (lvNEG) is confirmed by the formation of blasticidin-resistant 
colonies of lentivirus-infected HT-1080 cells stained with crystal violet.  
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To assess the therapeutic efficacy of specific genetic vaccination against the full-length 
DLK1 antigen, BALB/c mice bearing established day 7 RENCA tumors received a single 
intradermal injection of lvDLK1 or control lvNEG at a site distal to tumor (i.e., contralateral). 
Animals treated with lvDLK1 exhibited significant reductions in tumor growth compared with 
animals treated with lvNEG (Figure 10a). As was the case for DLK1 peptide-based vaccines, 
immunofluorescence microscopy analysis of tumor sections supported decreased vascularity and 
loss of (DLK1+) vascular pericytes (Figure 10b), and increased presence of the CXCR3 ligand 
chemokine, CXCL10, and VCAM1+CD31+ VEC in the TME of mice treated with lvDLK1 
versus lvNEG (Figure 10c,d). Enhanced expression of CXCL10 and VCAM1 in the TME was 
associated with greater numbers of CD8+ TIL in mice receiving LvDLK1-based vaccines 
(Figure 10e). These findings suggest that immune targeting of DLK1 via a single administration 
of lvDLK1 can effectively limit tumor growth and induce a proinflammatory TME promoting 
the improved recruitment of TIL. 
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Figure 10. Recombinant lvDLK1-based vaccines are therapeutic and promote a type-1–polarized TME. 
(a–d) BALB/c mice were inoculated s.c. with RENCA tumor cells in the right flank on day 0. (a) After cohort (n = 
5) randomization for similar mean tumor size on day 10 post-tumor inoculation, mice were treated i.d. in the left 
flank with 40 or 200 transduction units (TU) of lvDLK1 or control virus, lvNEG. Tumor size was then monitored 
longitudinally. (b–e) On day 27 post-tumor inoculation, mice were euthanized, with harvested tumors fixed, 
sectioned and analyzed by immunofluorescence microscopy for expression of (b) CD31 (green) and DLK1 (red) 
with white arrows indicating DLK1+ cells, (c) CXCL10, (d) co-localization of VCAM1 with CD31, and (e) 
CD8+ TIL (green) and NG (red). Histograms to the right of images reflect mean fluorescence intensity quantitation 
of the indicated markers (±SD) from three independent fields per slide as described in Materials and Methods. Data 
are representative of three independent experiments performed. *P < 0.05 versus control treatments (analysis of 
variance). i.d., intradermal. 
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2.4.4 Vaccination with lvDLK1 normalizes the RENCA vasculature 
It has been suggested that the tumor-associated vasculature of mice deficient in immature 
pericytes appears “normal” with minimal arborization and reduced vascular permeability [264], 
supporting therapeutic strategies to selectively reduce or eradicate immature vascular pericytes 
within tumor sites. Given the ability of our lvDLK1-based genetic vaccine to reduce the content 
of DLK1+ (immature) pericytes in the tumor stroma, we sought further evidence supporting 
therapeutic vascular remodeling as a consequence of treatment with this modality. We noted that 
RENCA tumors harvested from mice treated with lvDLK1 appeared “anemic” when compared to 
control tumors (Figure 11a), a subjective index that was subsequently confirmed based on an 
analysis of hemoglobin content in tumor lysates (Figure 11b). When we analyzed tumors for 
expression of NG2 using immunofluorescence microscopy, we observed that animals vaccinated 
with lvDLK1 exhibited tumors with significant reductions in numbers of NG2+ pericytes in their 
TME versus tumors from animals vaccinated with lvNEG (Figure 11c,d). Residual tumor 
pericytes in lvDLK1-treated animals were tightly approximated to CD31+ VEC, unlike the 
randomly distributed pattern of pericytes detected in the stroma of tumors isolated from control 
mice. To investigate changes in tumor vascular permeability, vaccinated animals received 
intravenous injections of two fluorescently labeled probes, tomato lectin-FITC to bind/mark the 
vascular endothelium and small 20  nm (red) FluoSpheres to determine vessel leakiness into 
tissue. When compared with controls, the tumor blood vessels in mice vaccinated with lvDLK1 
displayed a simple tubular architecture devoid of extensive branching (Figure 12a). 
Furthermore, while the perivascular stroma of tumors in control animals was littered with the red 
FluoSpheres, these probes were virtually undetected in tumors harvested from lvDLK1-
vaccinated mice, consistent with diminished vascular permeability in the TME of these latter 
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animals (Figure 12a). These data suggest that immunization against DLK1 allows for the 
immunotherapeutic “normalization” (i.e., reduction in blood vessel numbers and arborization, 
reduced vascular permeability) of tumor blood vessels in vivo. 
 
Figure 11. Recombinant lvDLK1-based vaccines promote normalization of the tumor vasculature. 
Mice bearing day 10 RENCA tumors were treated with 200 TU of lvDLK1 or lvNEG as outlined in Figure 10. On 
day 27 post-tumor inoculation, mice were euthanized and the (a) tumors were resected and evaluated 
macroscopically and (b) for hemoglobin content. In c and d, tumor sections were analyzed by immunofluorescence 
microscopy for expression of CD31 (green) and NG2 (red). In e, 6 µm sections were imaged by wide field 
microscopy, while in d, 30 µm sections were imaged by confocal microscopy to generate 3D reconstructions. For e, 
mean data ± SD of three independent fields per slide in c is reported for each group from one representative 
experiment of three performed. (f) The percentage of NG2 fluorescence signal overlapping CD31 fluorescence 
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signal was calculated using Metamorph software as described in Materials and Methods, and is reported as mean ± 
SD of three independent fields per slide. *P < 0.05 for lvDLK1 versus lvNEG (t-test). 
 
 
Figure 12. Recombinant lvDLK1-based vaccination reduces tumor vascular permeability resulting in the 
development of apoptotic “dead zones” in the TME. 
In repeated experiments as outlined in Figure 10, (a) treated mice received intravenous injections of tomato lectin-
FITC to label vascular endothelium (green) and 20  nm FluorSpheres to assess vascular permeability (red) on day 24 
post-tumor inoculation. Whole tumor tissue was then imaged immediately by confocal microscopy at a depth of 17 
µm. *P < 0.05 for lvDLK1 versus lvNEG (t-test). (b) On the same day, unlabeled mice were euthanized, with 
tumors resected, fixed, sectioned, and analyzed for expression of CD31 (green) and apoptotic nuclear staining with 
TUNEL reagent (red). Histograms to the right of images reflect mean fluorescence intensity quantitation of the 
indicated markers (±SD) from three independent fields per slide as described in Materials and Methods. Data are 
representative of three independent experiments performed. *P < 0.05 for lvDLK1 versus lvNEG (t-test). 
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2.4.5 Therapeutic vaccination with lvDLK1 results in increased cellular apoptosis in the 
treated TME 
Given the apparent trimming of vascular branches in the RENCA TME, and reduction in 
vascular permeability after vaccination with lvDLK1 (but not lvNEG), we hypothesized that 
plasma nutrients required for sustaining tumor cell viability would be limited to regions adjacent 
to the remaining normalized blood vessel network. TUNEL analyses revealed that indeed, the 
level of cellular apoptosis in the TME of lvDLK1-treated mice was substantially increased when 
compared with tumors isolated from control treated animals (Figure 12b). Furthermore, virtually 
all apoptotic events (i.e., “dead zones”) in RENCA tumors isolated from lvDLK1-vaccinated 
mice were located in tissue regions >~60 µm away from residual CD31+ blood vessels in planar 
tissue imaging analyses (Figure 12b). 
2.4.6 Therapeutic vaccination with lvDLK1 results in reduced hypoxia and a lower 
incidence of cell populations expressing hypoxia-responsive markers in the TME 
Hypoxia frequently occurs in solid cancers as a consequence of inefficient perfusion of oxygen 
into tumors by “aberrant” blood vessels [278, 279], resulting in reduced recruitment and function 
of TIL, increased prevalence of immunosuppressive cells/modulators, dysregulated angiogenesis, 
and the accumulation of “stem-like” cell populations (i.e., cancer stem cells/tumor initiating 
cells, cells undergoing epithelial-to-mesenchymal transition) in the TME [280, 281]. To 
investigate changes in hypoxia within tumors after vaccination with lvDLK1 versus lvNEG, we 
injected mice intraperitoneally (i.p.) with pimonidazole (a hypoxia marker that undergoes 
reductive activation and then conjugates to thiol-containing proteins specifically in hypoxic cells, 
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allowing for immunohistochemical detection of tissue regions exhibiting low (<1.3%) 
O2 tension) [282]. Using this imaging technology, we found that tumors isolated from mice 
receiving lvDLK1 vaccines had a very low hypoxic index when compared to tumors culled from 
control animals (Figure 13a). Given this large reduction in TME hypoxia postvaccination with 
lvDLK1, we next investigated treatment impact on expression of hypoxia-responsive gene 
products associated with immature vascular stromal cells (i.e., RGS5) and/or stem-like cell 
populations (i.e., Jarid1B aka histone demethylase lysine demethylase 5b; CD133, CD44) [283-
285]. Immunofluorescence microscopy analysis of day 27 tumor sections revealed that the 
expression of these markers was coordinately reduced in RENCA tumors after host vaccination 
with lvDLK1 (Figure 13b–f). When taken together, these data indicate that vaccination with 
lvDLK1 results in the recovery of normoxia in the TME in association with the conditional 
alteration in the phenotype (and presumably function) of a range of stromal cell 
subpopulations in vivo. 
2.4.7 Loss of DLK1 expression in the TME after therapeutic vaccination with lvDLK1 
leads to increased locoregional activation of NOTCH 
Since lvDLK1-based vaccination leads to loss of DLK1 expression in the TME (Figure 10) and 
DLK1 represents a functional inhibitor of NOTCH signaling [242], we hypothesized that this 
therapeutic vaccine would promote enhanced canonical NOTCH signaling in therapeutic 
RENCA TME. As shown in Figure 14a,b, RENCA tumors isolated from lvDLK1-treated (but 
not control) mice contained cells strongly expressing cytoplasmic/nuclear Hes1 protein, a 
NOTCH transcriptional target required for the tumor suppressor action of activated NOTCH 
[222, 267]. Hes1+ cells included both CD31+ VEC and non-VEC stromal cell populations in the 
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TME (Figure 14a). Corollary gene array analyses also supported the enhanced transcription of 
numerous NOTCH target genes (including the canonical NOTCH ligands (DLL1, DDL3, DLL4, 
and Jag1/2) and the NOTCH1-4 receptors, among others), but not control β2-microglobulin, in 
lvDLK1- versus lvNEG-treated tumors (Figure 14c). 
 
 
Figure 13. Recombinant lvDLK1-based vaccines promote normoxia in the TME in association with the loss of 
cells bearing stem cell-like phenotypes. 
Mice bearing day 10 RENCA tumors were treated with 200 TU of lvDLK1 or lvNEG as outlined in Figure 10. (a) 
On day 21, mice were injected intraperitoneally with the hypoxia probe pimonidazole hydrochloride and euthanized, 
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with tumors resected, sectioned, and analyzed by HRP immunohistochemistry. (b–e) Day 21 tumor-bearing mice 
that did not receive pimonidazole hydrochloride were euthanized, with tumors harvested, fixed, sectioned and 
analyzed by immunofluorescence microscopy for expression of (b) CD31 and RGS5, (c) Jarid1b, (d) CD133, and 
(e) CD44. (f) Histograms to the right of panel b–e images reflect mean fluorescence intensity quantitation of the 
indicated markers (±SD) from three independent fields per slide as described in Materials and Methods. Data are 
representative of three independent experiments performed. *P < 0.05 for lvDLK1 versus lvNEG (t-test). TME, 
tumor microenvironment; TU, transduction unit. 
 
2.4.8 Therapeutic benefits associated with lvDLK1-based genetic vaccination are partially 
dependent on canonical NOTCH signaling 
To determine the importance of canonical NOTCH signaling on the antitumor efficacy of genetic 
vaccination against DLK1, we immunized BALB/c mice bearing established s.c. RENCA tumors 
with lvNEG or lvDLK1 as described in Figure 10a, with cohorts of lvDLK1-vaccinated animals 
injected i.p. with the γ-secretase inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)-
phenylglycine t-butyl ester; which inhibits the generation of the NOTCH intracellular domain 
required for downstream NOTCH signaling events, ref. [286]) or vehicle control DMSO. As 
shown in Figure 14d, administration of DAPT partially suppressed the antitumor action of 
lvDLK1-based therapeutic vaccination. 
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Figure 14. Treatment with lvDLK1 vaccines results in NOTCH activation in the TME, which is partially 
responsible for the antitumor effectiveness of this treatment strategy. 
(a) Tumor sections were isolated as described in Figure 10 and evaluated by fluorescence microscopy using specific 
antibodies against CD31 (green) and Hes1 (red). DAPI counterstaining was used to image cell nuclei (blue). White 
arrows in image insets indicate Hes1+CD31+ VEC. (b) Mean fluorescence intensity quantitation of Hes1 protein 
expression (±SD) from three independent fields per slide is reported as described in Materials and Methods. Data are 
representative those obtained in three independent experiments performed. *P < 0.05 (t-test). (c) mRNA transcripts 
of NOTCH target genes were analyzed using an reverse transcription-PCR gene array. The ratio of transcript levels 
for a given gene product among total tumor mRNA isolated from lvDLK1- versus lvNEG-treated mice is reported. 
Negative control transcript = β2-microglobulin (beta 2-m). (d) Established day 8 s.c. RENCA tumors were treated 
with 200 TU of lvNEG or lvDLK1 (i.e., VAC) as described in the Figure 10a legend and Materials and Methods. 
DAPT (in DMSO; depicted as small gray ovals labeled “D” on the x-axis) or vehicle control DMSO was then 
provided as indicated for three consecutive days/week/cycle for two cycles beginning on day 12 post-tumor 
inoculation. Tumor size was then monitored longitudinally. *P < 0.05 for lvDLK1 + DAPT treatment versus 
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lvDLK1 treatment; also P < 0.05 for the lvDLK1 + DAPT and lvDLK1 treatments versus lvNEG control treatment 
on days ≥15 post-tumor inoculation (analysis of variance). DAPI, 4′,6-diamidino-2-phenylindole; TME, tumor 
microenvironment; TU, transduction unit; VAC, vaccination. 
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2.5 DISCUSSION 
The major finding in this report is that DLK1 is a tumor pericyte-associated antigen that can be 
immunologically targeted via specific peptide- or gene-based vaccination in vivo, leading to the 
effective “normalization” of the vasculature in the TME and a drastic reduction in solid tumor 
(i.e., RENCA) growth in vivo. Effective therapeutic vaccination resulted in the activation of 
type-1 (IFN-γ–producing) DLK1-specific CD8+ T cells in the periphery and the improved 
recruitment of CD8+ T cells into/around residual blood vessels in the TME. Therapeutically 
normalized blood vessels in RENCA tumors exhibit a simplified conduit design with tightly 
approximated (abluminal) NG2+DLK1negRGS5neg mature pericyte populations that appear 
improved in their structural integrity based on a reduction in vascular permeability. RENCA 
tumors in DLK1-vaccinated mice became normoxic and displayed a dramatic increase in the rate 
of apoptotic death in regions of the tumor that were further away from residual blood vessels. 
The relationship between loss of hypoxia and promotion of tumor cell apoptosis in the 
therapeutic TME may not be intuitively obvious. We hypothesize that consistent with the 
paradigm of Jain [139], therapeutic vascular normalization results in the coordinate loss of 
vascular permeability and hypoxia in the TME. In turn, loss of hypoxia (and hypoxia-responsive 
genes such as HIF-1α) has been associated with enhanced rates of tumor cell apoptosis [287] and 
reduced expression of a broad range of tumor growth and survival/antiapoptotic gene products 
[288]. As such, under normoxic conditions post-therapy (as in the case of lvDLK1-based 
vaccination), tumor cells most removed from blood vessels may be rendered most susceptible to 
undergo apoptosis based on limited access to pro-survival/growth factor gradients emanating 
from normalized blood vasculature. Overall, our findings support a model in which specific 
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immune effector T cells may serve as regulators of the “angiogenic switch” [139, 197, 264, 266, 
278] by monitoring and controlling the status of DLK1+ pericytes within the TME. 
Vaccination against DLK1 also induced a proinflammatory TME based on the acquisition 
of activated VCAM1+ VEC and concomitant production of the CXCR3 ligand chemokine 
CXCL10, responsible for recruiting type 1 TIL. We hypothesize that an initial wave of DLK1-
reactive type-1 TIL results in perivascular secretion of IFN-γ and tumor necrosis factor-α in the 
TME, leading to locoregional upregulation of IFN-γ/tumor necrosis factor-α–responsive gene 
products such as VCAM-1 and CXCL10 [289]. Such alterations in the TME would then be 
expected to foster improved uptake of tumor debris (i.e., apoptotic bodies) by recruited/activated 
antigen-presenting cells and the corollary reiterative cross-priming of an expanded, protective T 
cell repertoire reactive against both tumor- and tumor vascular-associated antigens [197] that 
may be directed into the proinflammatory TME. 
Interestingly, a recent report by Reis et al [289], suggests that the conditional activation 
of the Wnt/β-catenin/NOTCH signaling pathway can lead to vascular normalization, as indicated 
by reduced vascular density and improved mural cell attachment, in intracranial murine glioma 
models. Our data support such a paradigm, with specific vaccination resulting in removal of 
DLK1 expression (and NOTCH antagonism) [242] in the TME. Such immune pressure improved 
NOTCH signaling based on a dramatic increase in the intratumoral expression of Hes1 protein 
and the transcriptional activation of multiple NOTCH target genes. The transcriptional profiling 
also supports differentially increased expression of Frzd2, Frzd4, Frzd7, and β-catenin (Ctnnb1) 
in RENCA tumors harvested from lvDLK1-vaccinated mice supporting the coactivation of 
canonical Wnt/β-catenin signaling [290] in the therapeutic TME, consistent with the model 
proposed by Reis et al [289]. As such, our data suggest that vaccination against DLK1 (as an 
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integral transmembrane protein or via its shed extracellular domain) [291]41 may derepress 
canonical NOTCH/Wnt/β-catenin signaling in endothelial cells (and other stromal cell 
populations) within the TME, thereby promoting vascular quiescence/normalization [242, 289, 
292]. Vaccination against DLK1 may also improve type-1 functionality of TAMs and DC 
(i.e., enhanced IL-12p70 and CXCL10 production) and T cells [293]. Indeed, we observed that 
the functional antagonism of NOTCH signaling in vivo (based on administration of the γ-
secretase inhibitor DAPT) partially ablated the antitumor benefits associated with lvDLK1-based 
therapeutic vaccination, suggesting a supporting role for canonical NOTCH signaling in 
treatment outcome. Future studies will investigate the potential role of Wnt/β-catenin signaling 
in therapeutic benefit associated with DLK1-based vaccines by applying specific inhibitors of 
these pathways in our therapeutic model. 
The TME of progressively growing, control RENCA tumors was enriched in cells 
expressing markers known to contain HRE in their promoter regions, such as CD44, CD133, and 
Jarid1B [283-285], that have been previously linked to cell populations with “stem-like” 
characteristics [280, 281]. Notably, the “normalized” TME after therapeutic vaccination with 
lvDLK1 was normoxic and largely devoid of cells expressing these hypoxia-responsive antigens. 
Although the most simplistic reason for this change reflects the transcriptional silencing of these 
gene products in the TME of lvDK1-vaccinated animals, it is also conceivable that the 
therapeutic TME is poor in recruiting cells bearing these phenotypic markers, and/or that the 
vaccine evoked corollary cross-priming [197, 275] of cytotoxic CD8+ T cell responses capable of 
eradicating CD44+, CD133+, and Jarid1B+ target cells in effectively treated RENCA tumors. 
With regard to the latter scenario, we currently plan to longitudinally evaluate the reactivity of 
the evolving therapeutic CD8+ T cell repertoire against peptide epitopes derived from the CD44, 
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CD133, and Jarid1B (as well as alternate “stem cell”-associated/hypoxia-responsive markers 
such as ALDH1, Oct4, and Nanog) [285] antigens in RENCA-bearing mice treated with DLK1 
peptide/gene-based vaccines. 
The antiangiogenic action mediated by the DLK1 vaccine-induced CD8+ T cell repertoire 
would be anticipated to differ, and likely complement, that of alternative pharmacological 
antiangiogenic treatment modalities such as antivascular endothelial growth factor antibodies 
(i.e., bevacizumab) and small molecule tyrosine kinase inhibitors [261, 294, 295]. In most cases, 
tumors treated with these agents rapidly become drug-refractory due to their adoption of 
compensatory growth/progression pathways. As such, DLK1-based vaccines could represent a 
logical second-line approach in the many cases of developed resistance to bevacizumab, 
sunitinib or similar antiangiogenic drugs. DLK1-based vaccines may also represent effective co-
first line therapeutic agents, since the specific activation, recruitment and function of anti-DLK1 
T effector cells in the TME would be anticipated to be improved by the coadministration of 
antiangiogenic tyrosine kinase inhibitor that reduce suppressor cell populations (most notably in 
RCC patients) and activate a proinflammatory TME in vivo [174, 175, 177]. Based on these 
expectations, we plan to evaluate the comparative therapeutic efficacy of combined sunitinib + 
lvDLK1 vaccination treatment in our existing s.c. RENCA model, as well as, in an orthotopic 
RCC model using RENCA.luc (RENCA cells transduced with luciferase cDNA) to allow for 
vital bioluminescence monitoring of tumor growth and metastasis. Although we have not 
observed signs of off-target autoimmune pathology as a consequence of DLK1-targeted 
vaccination (i.e., inhibition of cutaneous wound healing [197], tissue vasculitis; data not shown) 
to date, these new models will provide us with additional opportunities to investigate potential 
combination treatment-associated toxicities in future. 
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Consistent with our findings in the RENCA model, pericytes from freshly isolated human 
RCC (but not patient-matched normal adjacent kidney tissue) also differentially (over)express 
the DLK1 antigen in situ (Appendix Figure 1). When coupled with the knowledge that anti-
DLK1 CD8+ T cell responses can be developed from human cancer patients after in 
vitro sensitization [275], we believe that DLK1-based vaccines (as single agents or in 
combination approaches) represent attractive candidates for clinical translation in the setting of 
RCC and alternate well-vascularized forms of solid cancer. 
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3.1 ABSTRACT 
When compared to vascular cells in normal tissues, pericytes and (VEC) in tumor blood vessels 
exhibit altered morphology and epigenetic programming that leads to the expression of unique 
antigens that allow for differential recognition by CD8+ T cells. We have previously shown that 
the Notch antagonist delta-like homolog 1 (DLK1) is a tumor pericyte-associated antigen 
expressed in setting of melanoma and a range of carcinomas. In this report, we show that 
therapeutic vaccination against DLK1 in murine models results in slowed tumor growth, but also 
to the compensatory expression of the DLK1 homolog, DLK2, by tumor-associated pericytes. 
Vaccines targeting both DLK1 and DLK2 resulted in superior anti-tumor benefits in association 
with improved activation and recruitment of antigen-specific Type 1 CD8+ T cells, reduced 
presence of MDSC and Treg, and tumor vascular normalization. The anti-tumor efficacy of 
vaccines coordinately targeting DLK1 and DLK2 was further improved by inclusion of PD-L1 
blockade, thus defining a combination immunotherapy theoretically suitable for the treatment of 
a broad range of solid (vascularized) cancers. 
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3.2 INTRODUCTION 
Progressive neoplasms require an expansive blood vessel network to supply nutrients and 
oxygen, as well as, to expel metabolic wastes and carbon dioxide, making the tumor vasculature 
a viable target for interventional anti-cancer therapy [296]. Indeed, therapies integrating 
neutralizing anti-vascular endothelial growth factor (VEGF) antibodies or tyrosine kinase 
inhibitors (TKIs) that interfere with proangiogenic signaling pathways have exhibited some 
degree of therapeutic efficacy in the pre-clinical and clinical settings [297, 298]. However, the 
protective benefits resulting from anti-angiogenic therapies have typically proven to be transient 
in nature, with the consequent evolution of treatment-refractory disease [299]. Hence, there 
remains a great clinical need to develop novel anti-angiogenic therapies that are adaptive and 
support the sustained normalization of the tumor vasculature in cancer patients. 
Blood vessels in solid tumors differ structurally and functionally from those found in 
normal tissues. In normal tissues, vascular endothelial tubes are found in close physical 
approximation with abluminal pericytes, where these cell types communicate via intimate cell-
to-cell contact, as well as, via mutually secreted factors. This results in the coordinated 
proliferation and differentiation of VEC, and the formation of an efficient and organized mature 
blood vessel network. In stark contrast, in the TME, VEC-pericyte associations are estranged, 
resulting in highly-permeable blood vessels and a local tissue milieu that is characterized by high 
interstitial fluid pressure, acidosis and hypoxia [22, 25]. Such environmental stressors promote 
unique epigenetic programming amongst stromal cell populations that leads to abnormal 
genomic and proteomic profiles of tumor-associated VECs and pericytes [187, 300]. Notably, 
disease-associated tumor-blood vessel-associated antigens (TBVA) may be targeted 
immunologically by specific CD8+ T cells that can be elicited via active, specific vaccination. 
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Indeed, our lab has previously shown that TBVA-targeted vaccines are competent to promote 
therapeutic CD8+ T cell responses that are capable of extending overall survival in murine tumor 
models [197]. 
In a previous study (Chapter 2), we demonstrated that pericytes within human renal cell 
carcinoma (RCC) biopsies or in vivo grown murine renal carcinomas (RENCA) express 
abnormally high levels of the TBVA delta-like homolog 1 (DLK1), and that therapeutic 
vaccination against DLK1 in RENCA-bearing mice results in tumor growth inhibition, increased 
frequencies of CD8+ tumor infiltrating lymphocyte (TIL) and vascular normalization (VN; ref. 
[197]). Interestingly, DLK1 (over)expression has also been correlated to the malignant 
transformation of adipocytes and to cancer stemness in the setting of hepatocellular carcinomas 
and neuroblastomas [243-246]. DLK1 and its homolog, delta-like homolog 2 (DLK2), belong to 
the Notch EGF-like family of receptors and ligands. DLK1 and DLK2 both contain six EGF-like 
repeats in the extracellular region, a single transmembrane region, and a short intracellular tail 
[237, 251]. Despite lacking the characteristic Delta, Serrate, and Lag-2 (DSL) domain of 
canonical Notch ligands, DLK1 and DLK2 interact with Notch1 and serve as antagonists to 
DLL4- and Jagged1-mediated activation of Notch signaling [240, 241, 252] that are required for 
normal vascular maturation [301]. 
Consistent with previous reports that the Dlk1 and Dlk2 genes reciprocally regulate each 
other’s expression [251], we report that targeted therapeutic vaccination against DLK1 in 
RENCA-bearing mice leads to the loss of DLK1 expression in the TME, but also to a 
compensatory increase in the expression of DLK2 by tumor-associated vascular pericytes. We 
also show that combined vaccination against DLK1 and DLK2 leads to superior anti-tumor 
benefits when compared to vaccination against either single antigen in both the RENCA and B16 
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melanoma tumor models. The combined vaccine resulted in superior activation and recruitment 
of antigen-specific CD8+ TIL and to VN in the TME. In the B16 tumor model, tumor-associated 
antigen (TAA)-specific T cells were also activated as a consequence of combined DLK1 + 
DLK2-targeted vaccination, via an apparent “epitope spreading” mechanism. Furthermore, we 
demonstrate that the anti-tumor efficacy of DLK1/DLK2-targeted vaccines may be improved 
when further combined with programmed death ligand-1 (PD-L1) blockade, thus defining a 
combination immunotherapy suitable for the treatment of many solid forms of cancer.  
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3.3 MATERIALS AND METHODS 
3.3.1 Animals and cell lines 
Female 6-8 week old Balb/c and C57BL/6 mice were purchased from Jackson Laboratory and 
were maintained in a pathogen-free animal facility. All animals were handled under aseptic 
conditions per an Institutional Animal Care and Use Committee (IACUC)-approved protocol and 
in accordance with recommendations for the proper care and use of laboratory animals. The 
RENCA (CRL-2947) and B16-F10 (CRL-6475) cell lines were purchased from American Type 
Culture Collection. These cell lines were free of Mycoplasma contamination and were 
maintained in complete medium [CM: RPMI-1640 media (Gibco, Cat. No. 21870-076) 
supplemented with 10% heat-inactivated fetal bovine serum (Sigma, Cat. No. F442), Pen/Strep 
[100 µg/mL streptomycin and 100 U/mL penicillin (Gibco, Cat. No. 15140-22)], and 10 mmol/L 
L-glutamine (Gibco, Cat. No. 25030-081)] at 5% CO2 tension in a 37°C humidified incubator.  
3.3.2 Generation of bone marrow-derived DCs and DC-based vaccines  
Bone marrow precursors isolated from the tibias and femurs of mice were cultured for 5 days in 
CM supplemented with 1000 U/mL rIL-4 and 1000 U/mL rGM-CSF (both from Peprotech) to 
generate DCs. The resulting DCs were then purified using CD11c microbeads (Miltenyi, Cat. 
No. 130-108-338) according to the manufacturer’s instructions. To generate DC/adenovirus-
based vaccines, purified DCs were infected with rAd.mIL-12p70 at a multiplicity of infection 
(MOI) of 50, alone or in combination with or rAd.mDLK1 or rAd.mDLK2 (MOI = 100 each) 
and cultured for 2 days in rIL-4 and rGM-CSF supplemented CM, prior to harvest and use as 
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vaccines. All recombinant adenoviral vectors were produced and provided by the University of 
Pittsburgh Cancer Institute's Vector Core Facility (a shared resource). To generate DC/peptide-
based vaccines, DCs transduced with Ad.mIL-12p70 (DC.IL12; as described above) were pulsed 
with a pool of the DLK1158–166, DLK1161–169, and DLK1259–270 peptides (10 µM each; ref.[302]) 
for 2 hours. DLK1 peptides were synthesized by the University of Pittsburgh Cancer Institute’s 
Peptide Synthesis Facility (a shared resource) and analyzed for purity by the University of 
Pittsburgh Cancer Institute's Protein Sequencing Facility (a shared resource). 
3.3.3 Generation of recombinant lentiviral vector 
Lentiviral vectors (lv) encoding mDLK1 (lvDLK1), mDLK2 (lvDLK2) and a reverse RGS5 
sequence (used as a negative control vector designated as lvNEG) were generated as previously 
described [302]. Briefly, full-length murine DLK1, DLK2, and reverse RGS5 (control) were 
cloned into pLenti6/V5 D-TOPO using the Lentiviral Directional TOPO Expression Kit 
(Invitrogen, Cat. No. K495000). To produce the lentiviral vectors, 293FT cells (Invitrogen, Cat. 
No. R700-07) were transfected with the pLenti plasmids with DLK1, DLK2 or control inserts 
using ViraPower Packaging Mix (Invitrogen, Cat. No.44-2050) combined with Lipofectamine 
2000 (Invitrogen, Cat. No. 11668019) according to the manufacturer's instructions. The lentiviral 
vectors were collected using a Fast-Trap Virus Purification and Concentration kit (Millipore, 
Cat. No. FTLV00003) 48 hours after the transduction. Lentiviral titers were determined via 
blasticidin-resistance assay (Invitrogen, Cat. No. R210–01) in HT1080 cells (kindly provided by 
Dr. Chuanyue Wu, University of Pittsburgh, Pittsburgh, PA) according to the manufacturer's 
instructions. 
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3.3.4 Animal experiments 
Balb/c mice received subcutaneous (s.c.) injection of 106 RENCA cells on the right flank. Six 
days after tumor inoculation, the animals were randomized into cohorts of five mice, with each 
cohort exhibiting comparable mean tumor sizes. For the DC/peptide-based vaccine experiments, 
RENCA-bearing mice were injected s.c. on the left flank (i.e. contralateral to tumor) with 100 µl 
PBS, 106 DC.IL12 or 106 DC.IL12 that had been pre-loaded with an equimolar (10 µM) mixture 
of DLK1 peptides on Days 7 and 14 post-tumor inoculation. For the lentiviral vaccine 
experiments, RENCA-bearing mice (on day 10 post-tumor inoculation) received intradermal 
injection of 50 µL PBS, 104 transduction units (TU) of lvNEG, 104 TU lvDLK1, 104 TU lvDLK2 
or 104 TU lvDLK1 + 104 TU lvDLK2. The dose of 104 TU was selected for analysis based on 
previous results using lvDLK1-based therapeutic vaccines in the RENCA model [302]. For the 
checkpoint inhibitor experiments, 200 µg PD-L1 blocking antibody (BioXCell, Cat. No. 
BE0101) was administered via i.p. injection into lentivector-vaccinated RENCA-bearing mice on 
days 7, 10, 13, and 17 after tumor injection. C57BL/6 mice received s.c. injections of 105 B16-
F10 cells on the right flank. Six days post-tumor inoculation, the animals were randomized into 
cohorts of five. On days 7 and 14 post-tumor inoculation, tumor-bearing mice received s.c. 
injection of 100 mL PBS, 106 DC.IL12, 106 DC.IL12.DLK1, 106 DC.IL12.DLK2 or 106 
DC.IL12.DLK1 + 106 DC.IL12.DLK2 on their left flank. Tumor size was assessed every 3-4 
days using a vernier caliper. Data are reported as mean tumor area ± SEM. 
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3.3.5 Stromal cell isolation  
Kidneys and tumors were isolated from control or vaccinated mice 21 days after initial tumor 
inoculation. After the tissues were mechanically minced and enzymatically digested with 0.5 
mg/mL collagenase IA (Sigma, Cat. No. C5894), 0.5 mg/mL collagenase II (Sigma, Cat. No. 
C1764), 0.5 mg/mL collagenase IV (Sigma, Cat. No. C1889), and 20 U/mL DNase I (Sigma, 
Cat. No. D5025), the resulting single cell suspensions were labeled with anti-mouse CD45-APC 
(BD Biosciences, Cat. No. 559864), anti-mouse CD34-FITC (eBioscience, Cat. No.11-0341-82), 
and anti-mouse CD146-PE (BD Biosciences, Cat. No. 562196). The cells were flow sorted into 
pericytes (CD45negCD34negCD146+) and VECs (CD45negCD34+CD146+) using a FACSAria II 
Cell Sorter (BD Biosciences). Sorted cells were > 95% pure for the specified phenotype. 
3.3.6 Real time PCR  
Messenger RNA from whole murine RCC tumors and murine kidney- and murine RCC-
associated pericytes and VECs was isolated using the RNeasy Plus Micro kit (Qiagen, Cat. No. 
74034) according to the manufacturer’s instructions. cDNA was then generated from the RNA 
samples using the High Capacity RNA-to-cDNA kit (Applied Biosystems, Cat. No. 2017-08-31) 
and real-time PCR was performed using the Fast SYBR Green Master Mix (Applied Biosystems, 
Cat. No. 2017-07-31). PCR reactions were performed in duplicate on a StepOnePlus real-time 
PCR thermocycler (Applied Biosystems) using the primers listed in Table 1 and cycling 
conditions of 95°C for 20 minutes, then 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds 
followed by post-amplification melting curve analysis at 95°C for 15 seconds and 60°C for 1 
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minute. Assays were normalized to HPRT1 gene (Qiagen, Cat. No. 249900) and the results were 
analyzed by the 2-ΔΔCt method.   
Table 1. qPCR primers 
Primer name Sequence 
mDLK1 forward TGTGACCCCCAGTATGGATT 
mDLK1 reverse CCAGGGGCAGTTACACACTT 
mDLK2 forward GCCTGCCAGAGCGGATGAC 
mDLK2 reverse CACACCTGCAGGAGCCGTC 
mPDGFR forward GACATTGAGTCCCCCAGCTA 
mPDGFRb reverse GAGCACTGGTGAGTCGTTGA 
Igf1r forward CTGATGTCTGGTCCTTCGGG 
Igf1r reverse CACCCTCCATGACGAAACGA 
Vegfr1 forward TACCTCACCGTGCAAGGAAC 
Vegfr1 reverse AAGGAGCCAAAAGAGGGTCG 
Vegfr2 forward GCTCATCATCCTAGAGCGCA 
Vegfr2 reverse ATGGTCTCGCCAATGGTTGT 
Vegfr3 forward GATGCTGAAAGAGGGCGCTA 
Vegfr3 reverse ACGTTGAGATGGTTGCCGAT 
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3.3.7 Fluorescent imaging of tumors 
Tumor tissue samples were fixed in 2% paraformaldehyde for 2 hours and dehydrated in 30% 
sucrose for 24 hours at 4°C. Six-micron tissue sections were analyzed using specific pAb against 
mNG2 (gift from Dr. William Stallcup, Sanford Burnham Prebys Medical Discovery Institute), 
mDLK1 (Santa Cruz Biotechnology, Cat. No. sc-25437), mDLK2 (Aviva Systems Biology, Cat. 
No. ARP49784_P050), mCD31 (BD Biosciences, Cat. No.550274), mVCAM1 (R&D, Cat. No. 
AF643), mNICD1 (Abcam, Cat. No. ab8925), mHes1 (Miltenyi, Cat. No. AB5702), and mCD8 
(BD Biosciences, Cat. No. 558733) paired with secondary antibodies donkey anti-guinea pig 
Cy3 (Jackson ImmunoResearch, Cat. No. 706-165-148), donkey anti-goat Cy3 (Jackson 
ImmunoResearch, Cat. No. 705-165-147), donkey anti-rabbit Alexa Fluor 488 (Molecular 
Probes, Cat. No. A-21206) or donkey anti-rat Alexa Fluor 488 (Molecular Probes, Cat. No. A-
21208) via immunofluorescence microscopy using a cold CCD camera (Olympus Magnafire; 
Olympus; Olympus, Central Valley, PA) to collect wide-field images. The Metamorph software 
(Molecular Devices, Downingtown, PA) was used to determine fluorescence signals over 
background and to measure individual structures as the integration of pixels (total number of 
positive pixels in structure above background) multiplied by the brightness of each pixel in grey 
scale. The same software was used to measure co-localization of specific labeled markers.  
3.3.8 In vitro evaluation of Ag-specific CD8+ T cell responses 
To evaluate specific CD8+ T cells responses in vaccinated tumor-bearing mice, spleens were 
harvested from animals 14 days after lentiviral injection or 7 days after the second 
DC/adenovirus vaccination. Splenocytes were re-stimulated in vitro with syngeneic DCs 
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transduced with mDLK1 and mDLK2 recombinant adenovirus for 5 days (1:10 DC:splenocyte 
ratio). Afterwards, CD8+ T cells were isolated from the splenocytes using a CD8+ T cell 
enrichment kit (Stemcell Technologies, Cat. No. 19753A) and were then assessed for antigen-
specific secretion of IFN-γ (Mabtech, Cat. No. 3321-3-1000 and 3321-6-250) or granzyme B 
(R&D, Cat. No. SEL1865) via ELISPOT, or by intracellular staining for IFN-γ (BD Biosciences, 
Cat. No. 554714) and flow cytometry according to manufacturer’s protocol. To test for anti-
DLK1 and anti-DLK2-specific responses, syngeneic DCs transduced with rAd encoding mDLK1 
or mDLK2, respectively, were used as target cells. To test for Ag-specific responses in 
melanoma models, C57BL/6 DCs were pulsed with 1 µM human gp10025-33 (Anaspec, Cat. No. 
AS-62589) or 1 µM mouse TRP2180-188 (AnaSpec, Cat. No. AS-61058), and used as stimulator 
cells. As positive controls, purified T cells or splenocytes were stimulated with 2 µg/mL conA 
(Sigma, Cat. No. C0412) or 0.5 µg anti-mCD3e antibody (eBioscience, Cat. No. 16-0031-82) 
along with 0.5 µg anti-mCD28 antibody (eBioscience, Cat. No. 16-0281-82). 
3.3.9 Flow cytometry 
Spleens and tumors were harvested from mice 14 days after lentiviral injection or 7 days after the 
second DC/adenovirus vaccination, with single-cell suspensions then prepared as previously 
described (9,10). Fluorescently-labeled antibodies against the following target molecules were 
used for cell surface staining: CD3e-BUV395 (BD Biosciences, Cat. No. 563565), CD4-
PEDazzle (Biolegend, Cat. No. 100566), CD8a-FITC (BD Biosciences, Cat. No. 553031), CD8-
PECy7 (BD Biosciences, Cat. No.552877), CD11b-APC (eBioscience, Cat. No.17-0112-82), Gr-
1-PE (BD Biosciences, Cat. No. 553128), PD-1-FITC (eBioscience, Cat. No. 11-9985-81), and 
PD-L1-PE (Biolegend, Cat. No. 124308). Cell staining was performed in FACS buffer (PBS 
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with 5% FBS and 0.1% NaN3). To stain for intracellular cytokine, the BD Cytofix/Cytoperm kit 
(BD Biosciences, Cat. No. 554714) was used with anti-IFNγ-PE (BD Biosciences, Cat. No. 
554412). To stain for intracellular transcription factors, FoxP3/Transcription factor staining 
buffer set (eBioscience, 2017-11) was used with the anti-FoxP3-APC (eBioscience, Cat. No.17-
5773-82) and anti-Tbet-APC (Biolegend, Cat. No. 644814) antibodies. 
3.3.10 Statistical Analyses 
Comparisons between groups were performed using a two-tailed Student’s t-test or analysis of 
variance (ANOVA; one-way or two-way) with Tukey's post-hoc analysis. All data were analyzed 
using GraphPad Prism software, version 6.07 (GraphPad Software, Inc., La Jolla, CA). 
Differences between groups with a P value <0.05 were considered significant. 
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3.4 RESULTS 
3.4.1 Treatment of RENCA tumor-bearing mice with DLK1 peptide-based vaccine leads 
to a compensatory increase in DLK2 expression in tumor-associated pericytes 
We have previously reported that pericytes within murine RENCA and melanoma TME 
overexpress DLK1 protein when compared to their normal tissue counterparts, permitting the 
differential recognition of tumor-associated pericytes by DLK1-specific CD8+ T cells (Chapter 
2; [197, 302]). Indeed, treatment of RENCA-bearing Balb/c mice with DC/DLK1 peptide-based 
vaccines or lentivirus-based DLK1 genetic vaccines effectively promote the activation and 
recruitment of Type-1 anti-DLK1 CD8+ TIL in concert with removal of DLK1+ target cells in the 
TME and delayed tumor growth (Chapter 2; [302]). Since DLK1 and its homolog, DLK2, both 
function as Notch antagonists and may counter-regulate each other’s expression [252], we first 
investigated DLK2 expression in the tumor stroma of untreated versus DLK1-vaccinated mice. 
We confirmed that RENCA-bearing mice receiving DC/DLK1 peptide-based vaccines on days 
10 and 17 post-tumor inoculation exhibited slowed disease progression when compared with 
cohorts of animals that were left untreated or that had been treated with DC control (no peptide) 
vaccines (Figures 15a and 15b). To determine whether DLK2 was differentially expressed by 
pericytes and VECs in tumor vs. (tumor-uninvolved) kidneys +/- treatment, tissues were 
enzymatically-digested, with each cell type was then isolated from single-cell suspensions by 
fluorescence-activated cell sorting (Figure 15c). mRNA was extracted from the sorted cells and 
real-time PCR was performed to quantify the amount of DLK2 transcript in each sample. We 
observed that DLK2 transcript was minimally expressed by pericytes and VECs sorted from 
normal kidneys and untreated RENCA tumors. However, DLK2 mRNA was enriched in tumor-
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associated pericytes isolated from animals that had been vaccinated against DLK1 (Figure 15d). 
This observation was confirmed in immunofluorescence microscopy analysis of tumor sections, 
where DLK2 protein was selectively (co)expressed with NG2+, a marker that is specifically 
expressed by pericytes but not by RENCA cells [302], within the TME of DLK1-vaccinated 
mice. DLK2 was not expressed within the tumors of mice in any other treatment cohort (Figure 
15e). These data suggest that DLK2 may represent a “covert” antigen expressed by tumor-
associated vascular pericytes that can be therapeutically targeted in the cancer setting, 
particularly under conditions in which DLK1 expression is silenced (i.e. as a consequence of 
targeted vaccination). 
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Figure 15. Vaccination of RENCA-bearing mice against DLK1 results in slowed tumor growth, the loss of 
DLK1+ pericytes in the TME, and a compensatory increase in DLK2 expression by tumor-associated 
vascular pericytes. 
(A) Female Balb/c mice with established day 10 s.c. RENCA tumors on their right flanks were treated with s.c. 
injection (left flank) of PBS, 106 DCs transduced with rAd.IL12 (i.e. DC.IL12) or DC.IL12 pulsed with DLK1-
derived peptide epitopes (i.e. DC.IL12.DLK1) per Materials and Methods. An identical s.c. booster vaccination was 
provided on day 17 post-tumor inoculation. (B) Tumor growth was monitored every 3-4 days and is reported as the 
mean ± SEM for 5 animals per group. *P < 0.05, two-way ANOVA. (C) On day 21, tumor tissues and (tumor-
uninvolved kidneys from matched animals) were harvested and then digested mechanically and enzymatically as 
described in the Materials and Methods, yielding single-cell suspensions. Live cells (DAPI negative) cells were 
flow-sorted to select for CD45-CD146+CD34- pericytes and CD45-CD146+CD34+ VEC populations. (D) Total 
mRNA was isolated from sorted populations of pericytes and VECs and analyzed for DLK2 expression by 
quantitative real-time PCR. Relative mRNA expression was normalized to HPRT1 expression. *P < 0.05, one-way 
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ANOVA compared with kidney pericyte DLK2 levels. In (E), RENCA tissue sections were analyzed for expression 
of DLK2 (green) in NG2+ pericytes (red) by immunofluorescence microscopy. Scale bar = 1mm. All data are 
representative of those obtained in 2 independent experiments. 
 
 
Figure 16. Production of recombinant lvDLK2 lentivirus. 
(A) Schematic of the plasmid construct encoding full-length murine DLK2. The plasmid contains the following 
elements: pRSV/5’ LTR, RSV LTR and HIV LTR chimeric promoter, HIV psi (Ψ) packaging sequence, HIV Rev 
response element (RRE), CMV promoter, full length murine DLK2 gene with V5 reporter tag, SV40p early 
promoter and origin, EM7 promoter, blasticidin gene,ΔU3/HIV 3′LTR self-inactivating system. This plasmid was 
subsequently transfected into 293T cells and the resulting cells analyzed for V5 protein expression by (B) 
immunofluorescence microscopy and (C) western blotting. Lentiviral vectors recombinant for murine DLK2 were 
then generated and used to infect HT-1080 cells. Live functional virus was confirmed by the (D) formation of 
blasticidin-resistant colonies imaged after crystal violet staining and by (E) western blotting for DLK2 after specific 
lentiviral infection with lvDLK2 vs. control virus (lvDLK1 or lvNEG). All data are representative of those obtained 
in 3 independent experiments in (B-D). Scale bar = 1 mm 
 89 
3.4.2 Coordinate vaccination with lvDLK1 + lvDLK2 provides superior therapeutic 
benefit against established RENCA tumors 
To test the hypothesis that therapeutic vaccination against both DLK1 and DLK2 would yield 
greater protection against tumor progression vs. single antigen-based vaccines, recombinant 
lentiviral vectors encoding full-length murine DLK1 (lvDLK1) or DLK2 (lvDLK2) were 
generated (Figure 16). Based on a previous report that single intradermal (i.d.) injection of a 
lentiviral vector-based vaccine results in sustained anti-tumor CD8+ T cell responses in vivo 
[277], we performed a single i.d. injection of lentiviral vectors (lvDLK1 +/- lvDLK2 or the 
lvNEG negative control virus) 7 days after the s.c implantation of RENCA tumor cells. Vaccines 
were provided on the contralateral flank to that in which the tumor was placed. Untreated 
animals were included as a negative control cohort. We then monitored tumor growth 
progression and specific T cell responses across all treatment groups. Consistent with our 
previous report [302], we confirmed that lvDLK1-based vaccination inhibited tumor growth 
(Figure 17a). However, tumor growth was inhibited to a greater degree in animals treated with 
the combined lvDLK1 + lvDLK 2 vaccine. Notably, therapeutic vaccination against DLK2 alone 
failed to impact tumor growth. As the target DLK2 protein was not highly-expressed in RENCA 
tumors unless DLK1 expression was first silenced in tumor pericytes (Figures 15d, 15e, 17e), 
this result might merely reflect the lack of a salient target within the TME for recognition by 
DLK2 vaccine-induced CD8+ T cells in mice vaccinated using only lvDLK2. Overall, we 
observed that the extent of tumor growth inhibition was associated with the degree of CD8+ TIL 
infiltration, with the most robust CD8+Tbet+ T cell infiltrates observed in the lvDLK1 + lvDLK2 
treatment cohort (Figures 17b and 17c).  
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We observed that increased CD8+ T cell infiltration of tumors in lvDLK1- and lvDLK1 + 
lvDLK2-vaccinated animals was associated with a significant decline in NG2+ pericytes within 
the TME (Figure 17b). These results are consistent with a model in which our lentivirus-based 
vaccines promote the activation of specific CD8+ T cells that target DLK1+/DLK2+ (NG2+) 
tumor-associated pericytes in vivo. To further monitor antigen-specific CD8+ T cell responses 
after lentivirus-based vaccination, DCs transduced with recombinant adenovirus encoding full-
length mDLK1 or mDLK2 were used to (re)stimulate splenocytes harvested from control or lv-
treated animals in vitro for 5 days. CD8+ T cells were then isolated from these cultures and 
DLK1- and DLK2-specific responses were subsequently analyzed in IFN-γ ELISPOT assays. 
We found that when applied individually, the lvDLK1 and lvDLK2 vaccines promoted DLK1- or 
DLK2-specific responses, respectively. Predictably, the combination lvDLK1 + lvDLK2 vaccine 
induced both DLK1- and DLK2-specific CD8+ T cell responses in treated animals (Figure 17d). 
We were also able to confirm the induction of DLK1-specific CD8+ T cell responses in the 
lvDLK1 and lvDLK1 + lvDLK2 treatment cohorts using DC pulsed with defined synthetic 
DLK1 peptide epitopes [302] as a stimulus in IFN-γ ELISPOT assays (Figure 18). 
Following the observation that the lvDLK1 + lvDLK2 vaccination induced the activation 
of DLK1- and DLK2-specific T cells, we next investigated how the various vaccine formulations 
affected DLK1 and DLK2 protein expression by cells within the tumor stroma. We determined 
that DLK1 expression by NG2+ pericytes was diminished after vaccination with lvDLK1 (either 
alone or in combination with lvDLK2; Figure 17e). Vaccination against lvDLK2 alone did not 
affect DLK1 expression in the TME, however, DLK2 became expressed by NG2+ pericytes after 
lvDLK1 vaccination (Figure 17f). Remarkably, co-vaccination using lvDLK1 and lvDLK2 
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resulted in NG2+ pericytes that failed to express either DLK1 or DLK2 in the therapeutic TME 
(Figure 17e, 17f).  
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Figure 17. Coordinate vaccination with lvDLK1 and lvDLK2 is immunogenic and therapeutic in the RENCA 
model. 
Female Balb/c mice bearing established day 7 s.c. RENCA tumors were treated with i.d. injection of PBS, 104 
lvNEG, 104 lvDLK1, 104 lvDLK2 or 104 lvDLK1 + 104 lvDLK2. (A) Tumor growth was monitored every 3-4 days 
through day 20, at which time the animals were euthanized. Tumor sizes are reported as the mean ± SEM for 5 
animals per group. *P < 0.05, two-way ANOVA. Tumors were then harvested to generate tumor sections or they 
were mechanically/enzymatically-digested to generate single-cell suspensions. (B) Tumor sections were analyzed by 
immunofluorescence microscopy for NG2+ pericytes (red) and infiltrating CD8+ T cells (green). Using Metamorph 
software (Materials and Methods), CD8+ T cell infiltrates and NG2+ pericytes in the images were quantified and 
reported as mean integrated fluorescence ± SEM. *P < 0.05 and **P < 0.01, one-way ANOVA (C) Flow cytometry 
was also performed on the resulting cell suspensions to quantify Tbet+ CD8+ TIL. Tumor sections were analyzed for 
CD8+ TIL (green) infiltration and NG2+ (red) expression. In (D), splenocytes harvested from day 21 tumor-beating 
mice were stimulated in vitro with syngeneic DC infected with rAd.DLK1 (DC.DLK1), rAd.DLK2 (DC.DLK2) or a 
mixture of both DC populations (i.e. DC.DLK1 + DC.DLK2) for 5 days. Responder T cells were the isolated and 
restimulated with control or rAd-infected DC as indicated for 18h, and the resultant culture supernatants analyzed 
for IFN-γ content using a cytokine-specific ELISPOT assay. *P < 0.05, one-way ANOVA. In (E) and (F), tumor 
sections were analyzed for NG2+ pericyte co-expression of DLK1 and DLK2, respectively, via immunofluorescence 
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microscopy. Scale bar = 1mm. Data in A, B, C, E, and F are representative of those obtained in 3 independent 
experiments. Data in D is representative of 2 independent experiments. 
 
 
Figure 18. CD8+ T cells in RENCA-bearing mice treated with lvDLK1 or lvDLK1 + lvDLK2 recognize 
peptide epitopes derived from DLK1. 
Female Balb/c mice bearing established day 7 s.c. RENCA tumors were treated with i.d. injection of PBS, 104 
lvNEG, 104 lvDLK1, 104 lvDLK2 or 104 lvDLK1 + 104 lvDLK2. On Day 21, splenocytes harvested from the treated 
and control mice were stimulated in vitro with DCs pulsed with a pool of the DLK1158–166, DLK1161–169, and 
DLK1259–270 peptide epitopes (10 µM each) for 5 days. Responder CD8+ T cells were the isolated and re-stimulated 
with DC (no peptide; negative control), DLK1 pooled peptide-pulsed DC or anti-CD3/CD28 (positive control) for 
18h in IFN-γ ELISPOT assays. Results are reported as the mean +/- SD of triplicate determinations. *P < 0.05. Data 
are representative of those obtained from 2 independent experiments performed. 
 
Since TBVA are overexpressed in the TME of solid cancers independent of tumor 
histology [197], TBVA-based vaccines should offer therapeutic benefit against a wide range of 
vascularized tumors, leading us to next evaluate the anti-tumor efficacy of DLK1- and DLK2-
based vaccines against (RENCA-unrelated) B16 melanomas established s.c. in C57BL/6 mice 
(Figure 19a). Syngenic DCs were infected with recombinant adenovirus encoding full-length 
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containing a progressively growing B16 melanoma. An identical booster vaccine was 
administered one week later. We observed that the combined DLK1 + DLK2-based vaccine 
yielded optimal anti-tumor efficacy in association with the induction of the most robust antigen-
specific CD8+ T cell responses (Figure 19b). Furthermore, we noted that successful vaccination 
against DLK1/DLK2 in these animals was also associated with the development of CD8+ T cell 
responses against the (vaccine-unrelated) melanoma antigen gp100 (Figure 19c), presumably via 
an “epitope spreading” mechanism.  
 
 
 
Figure 19. Combined vaccination against DLK1 and DLK2 provides superior therapy benefit against 
established s.c. B16 melanomas. 
On days 7 and 14 post-s.c. inoculation of B16 melanoma cells, mice were injected s.c. on the contralateral 
flank with 106 DC transduced with a recombinant adenovirus encoding murine (DC.IL12) +/- recombinant 
adenoviruses encoding murine DLK1 (DC.IL12.DLK1) or murine DLK2 (DC.IL12.DLK2) or both DLK1 and 
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DLK2 (DC.IL12.DLK1 + DC.IL12.DLK2). (A) B16 tumor growth was monitored and measured every 3-4 days, 
with tumor size reported as mean ± SEM (n = 5 mice/group). Splenocytes were harvested from the animals on day 
17 post-tumor inoculation and analyzed for (B) DLK1- and DLK2-specific CD8+ T cells via intracellular staining for 
IFN-γ, or for (C) gp100- and Trp2- specific CD8+ T cells using a granzyme B ELISPOT assay as described in 
Materials and Methods. *P < 0.05 and **P < 0.01. All data are representative of those obtained in 3 independent 
experiments. 
3.4.3 DLK1/DLK2-based vaccines promote VN within the TME 
Our ability to drive Type-1 CD8+ T cell responses against tumor-associated vascular pericytes 
using DLK1/DLK2-based vaccines, allows for the possibility of therapeutically proctoring a state 
of VN [303]. To investigate this further, tumor sections from treated vs. control mice were 
stained for the VEC marker CD31 and the pericyte marker NG2 (Figure 20a). Adopting the 
method of Weidner et al. [304], we quantified microvessel densities (MVD) and we observed 
that tumors in mice treated with lvDLK1- or lvDLK1 + lvDLK2-based vaccine exhibited 
significant vascular pruning when compared to tumors in control or lvDLK2-only vaccinated 
mice (Figure 20b). In addition, when pericyte-VEC co-localization was evaluated in tumor-
associated blood vessels, we observed that CD31- and NG2-associated fluorescent signals were 
also more closely associated with each other in the tumors of mice vaccinated with lvDLK1 or 
with combined lvDLK1 + lvDLK2 versus tumors in all other treatment cohorts (Figure 20c). 
Collectively, the decreased vascular arborization and increased NG2+ pericyte coverage of 
CD31+ vessels observed in the tumors of lvDLK1- or lvDLK1 + lvDLK2-treated mice is 
consistent with therapeutic VN as previously described by Jain [139]. Since tumor VN is also 
characterized by a loss of hypoxia (and a return to normoxia) within the TME [139, 305], we 
analyzed treated vs. control tumors for expression of the hypoxia-associated biomarker HIF-2α 
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[305-307]. We determined that tumors in mice vaccinated with lvDLK1 or (more so) lvDLK1 + 
lvDLK2 displayed significant reductions in HIF-2α transcript levels versus control-untreated 
tumors (Figure 20d), consistent with therapeutic VN in these treatment cohorts.  
We also observed that pro-angiogenic biomarkers were repressed as a consequence of 
lvDLK1/2-based vaccination. In particular, expression of VEGFR1 and VEGFR2 mRNA were 
significantly reduced in the TME of lvDLK1-treated animals, while transcript levels of VEGFR1, 
VEGFR2 and fibroblast growth factor receptor 1 (FGFR1) were coordinately decreased in the 
TME of mice treated with the combined lvDLK1 + lvDLK2 vaccine (Figure 20e).  
Lastly, combined vaccination against DLK1 and DLK2 led to an increase in expression 
of vascular cell adhesion molecule-1 (VCAM1) by tumor-associated VECs (Figure 20f), 
consistent with improved tumor infiltration by Type-1 (Tbet+) CD8+ T cells (Figure 17b, 17c).  
3.4.4 lvDLK1 + lvDLK2-based vaccination decreases frequencies of immunosuppressive 
cell populations in the TME.  
Tumor-associated hypoxia plays a critical role in the maintenance and regulatory activity of 
myeloid-derived suppressive cells (MDSC), as well as, regulatory T (Treg) cells in the TME 
[308]. As VN mitigates hypoxia in the TME (Figure 20d; ref. [139, 302]), one might predict that 
vaccines promoting VN would recondition the immunologic landscape within tumors to become 
less suppressive. We examined this hypothesis in the TME of mice receiving vaccine-based 
therapy and found that levels of both MDSC (Figure 21a) and Tregs (Figure 21b) were reduced 
to a greater extent in the tumors of mice treated with combined lvDLK1 + lvDLK2 vaccination 
versus all other treatment cohorts. 
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Figure 20. Coordinate vaccination with lvDLK1 and lvDLK2 results in tumor VN. 
(A) RENCA tumor sections from Fig. 15 were stained for NG2+ pericytes (red) and CD31+ VECs (green) to 
characterize blood vessel morphology. (B) Mean vessel density was determined by quantitating distinct (green) 
VECs or VEC clusters. (C) Colocalization of NG2+ (red) pericytes and CD31+ (green) VECs was determined using 
Metamorph software. (D-E) RNA extracted from Day 21 RENCA tumors was analyzed for HIF2α, VEGFR1, 
VEGFR2, and FGFR1 transcript levels by quantitative real-time PCR. In (E), tumor CD31+ VEC (green) were 
analyzed for co-expression of VCAM1 (red) by immunofluorescence microscopy. Scale bar = 1mm. *P < 0.05 and 
**P < 0.01, one-way ANOVA compared to the negative control (lvNEG). All data are representative of those 
obtained in 3 independent experiments. 
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Figure 21. Coordinate vaccination with lvDLK1 and lvDLK2 results in a superior level of reduction in Treg 
and MDSC content in the therapeutic TME. 
Day 21 tumors from untreated or treated mice per Fig. 1 were dissociated into single-cell suspensions and analyzed 
by flow cytometry for (A) CD11b+Gr1+ MDSC and (B) FoxP3+CD4+ Treg populations. Data are representative of 
those obtained in 3 independent experiments. 
3.4.5 lvDLK1 + lvDLK2-based vaccination combined with PD-L1 blockade further 
enhances therapeutic efficacy. 
Cancer vaccines have previously been shown to be both safe and immunogenic, but rarely 
curative, based on a variety of immune escape mechanisms employed by residual tumor cells, 
including elevated expression levels of immune checkpoint/co-inhibitory molecules [309, 310]. 
Transcript analysis of RENCA tumors vs. normal kidney tissue (from tumor-matched animals) 
revealed that RENCA tissues overexpress a number of co-inhibitory receptors including B7H3, 
Gal9, PD-L1 and PD-L2 (Figure 22a) that would be expected to negatively impact anti-tumor 
CD8+ T cell activity in vivo [309, 310]. Consistent with the known capacity of IFNγ to 
upregulate PD-L1 expression in some tumors [311], we observed that culturing RENCA cells in 
media supplemented with rmIFNγ resulted in increased PD-L1 expression (Figure 22b).  
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Figure 22. Expression of co-inhibitory molecules in RENCA tumors in vivo. 
(A) Female Balb/c mice (n=3) were inoculated s.c. with 1x106 RENCA cells and were left untreated. On Day 21, 
RNA was extracted from harvested tumors and analyzed for expression of B7H3, Gal9, PD-L1, and PD-L2 
transcripts via real-time PCR. *P < 0.05. (B) RENCA cells were incubated in complete RPMI media supplemented 
with 10 ng/ml rmIFN-γ. After 24 hours, tumor cells were harvested and analyzed for PD-L1 expression via flow 
cytometry. The presented data are representative of those obtained in 2 independent experiments. 
 
Since we noted a dramatic influx of inflammatory CD8+ TIL in RENCA tumors 
sponsored by combined lvDLK1 + lvDLK2 vaccination (Figures 17b, 17c), we next evaluated 
PD1 and PD-L1 protein expression levels on TIL and tumors, respectively, in treated vs. control 
tumor-bearing mice. We found that PD1 protein expression on CD8+ TIL was comparable across 
all cohorts (Figure 23a). On the other hand, PD-L1 protein expression on tumor cells was 
upregulated in lvDLK1- and lvDLK1 + lvDLK2-vaccinated mice when compared with mice in 
the other treatment cohorts (Figure 23b). Based on these findings, we next investigated the 
therapeutic benefit of combining lvDLK1 + lvDLK2-based vaccination with systemic delivery of 
an antagonist anti-PD-L1 antibody. We observed that the degree of RENCA growth inhibition 
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was greatest in animals that received the combined lvDLK1/lvDLK2 + anti-PD-L1 antibody 
treatment regimen versus cohorts of tumor-bearing mice receiving either the lvDLK1/lvDLK2 
vaccine alone or anti-PD-L1 monotherapy (Figure 23c). This superior level of anti-tumor 
efficacy was association with the greatest magnitude of increased recruitment/maintenance of 
Tbet+ CD8+ T cells within the TME (Figure 23d) and the greatest degree of reduction in 
CD4+FoxP3+ TIL (Figure 23e). 
 
 
Figure 23. PD-L1 blockade fails as a monotherapy against RENCA tumors, but improves the anti-tumor 
efficacy of combined lvDLK1 + lvDLK2 vaccination. 
(A) CD8+ TILs and (B) bulk RENCA single-cell suspensions (per Fig. 1) were analyzed for expression of PD-1 and 
PD-L1, respectively, by flow cytometry. In (C), mice bearing established day 7 RENCA tumors (right flank) were 
vaccinated i.d. with lvDLK1 + lvDLK2 (left flank) as a therapeutic vaccine. Anti-mPD-L1 blocking antibody was 
injected i.p. on days 7, 10, 13, and 17 post-tumor inoculation as described in Materials and Methods. Tumor growth 
was monitored longitudinally and is reported as the mean ± SEM for 5 animals per group. In (D), RENCA tumors 
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were harvested on day 26 and dissociated single-cell suspensions analyzed for (D) Tbet+CD8+ TILs and (E) 
FoxP3+CD4+ Tregs by flow cytometry. *P < 0.05 and **P < 0.01. 
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3.5 DISCUSSION 
An ideal cancer vaccine antigen is one that is overexpressed by cells within the TME versus 
normal tissues, allowing for selective T cell targeting of disease sites. We have previously 
reported that the non-canonical Notch ligand, DLK1, is overexpressed by vascular pericytes in 
murine colon and renal carcinomas, and melanomas, when compared to tumor-uninvolved 
kidneys in these same animals, and that vaccination against DLK1 is capable of yielding 
therapeutic anti-tumor benefits (Chapter 2; [302]). In the current report, we demonstrate that the 
expression of DLK2, a homolog of DLK1, is upregulated in tumor-associated vascular pericytes 
following successful DLK1-targeted vaccination, consistent with the reciprocal expression 
profiles of these two related Notch antagonists. Given this phenotypic adaptation by tumor 
pericytes, we hypothesized that a combination vaccine targeting both DLK1 and DLK2 would 
have greater potential to promote an extended state of VN in the TME in association with 
improved treatment benefits. Combined vaccination against DLK1 and DLK2 resulted in 
superior activation of peripheral Type-1 antigen-specific CD8+ T cell responses and more robust 
recruitment of T effector cells into the TME. Therapeutic TIL modified the tumor landscape by 
promoting the loss of DLK1+ and DLK2+ pericytes, effectively pruning immature tumor blood 
vessels. The normalization/maturation of the vascular network, which allows a switch from the 
hypoxic to a normoxic TME [312], also resulted in tumors that were coordinately deficient in 
CD11b+Gr1+ MDSCs and FoxP3+ Tregs that are typically associated with immunosuppression.  
Studies from other groups have previously shown that DLK1 and DLK2 reciprocally 
modulate each other’s expression [251, 252]. For instance, during murine neonatal liver 
development, when DLK1 expression is elevated during the first few days of life, DLK2 is 
absent, but once DLK1 expression starts to decline, DLK2 expression is turned on. Furthermore, 
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forced ectopic expression of DLK1 or DLK2 in cells results in the loss of expression of the 
alternate homolog. The mechanism responsible for the coordinated control of DLK1 and DLK2 
gene expression remains poorly-defined. When considered within the context of our DLK1-
based vaccine strategy, we hypothesize that the change in the oxygenation level in the 
therapeutically normalized TME may play a role in flipping a transcriptional switch favoring 
DLK2 expression. The DLK1 promoter contains hypoxia regulatory elements (HRE), placing 
gene expression under the control of the HIF-1α transcription factor [245]. On the other hand, 
DLK2 transcription does not seem to be directly driven by hypoxia but is rather controlled by the 
Sp1 and KLF4 transcription factors [313, 314], whose activities may be augmented under 
normoxic conditions [315, 316].  
The role of DLK1 and DLK2 in blood vessel formation and maintenance in normal and 
disease settings remains underinvestigated. Our previous and current studies, however, suggest 
that DLK1 and DLK2, when expressed by tumor pericytes, contribute to pathological 
characteristics of the tumor blood vessel network by inhibiting Notch1 signaling in the 
perivascular region. Notch1 signaling in normal endothelial cells is critical in embryonic 
vascular development, endothelial cell fate determination, and vascular homeostasis [317]. Notch 
signaling also plays a role in tumor neovascularization, as suppression of the DLL4-Notch1 
interaction leads to the formation of excessive immature blood vessel branches as a result of 
uncontrolled endothelial proliferation [20, 229, 230]. Both DLK1 and DLK2 block downstream 
Notch1 receptor signaling by interacting with the EGF-like repeat 12 of the receptor [252], 
known to be the binding site for canonical ligands [318, 319]. Thus, DLK1 and DLK2 impede 
Notch signaling by blocking receptor activation and by competing with ligands for binding sites. 
Vaccine-induced removal of DLK1+ and DLK2+ pericytes from the TME leads to VN that is 
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correlated with NICD activation and Hes1 expression in endothelial cells (Appendix Figure 2). 
Consistent with a model in which activation of the Wnt/β-catenin/NOTCH signaling pathway in 
tumor endothelia leads to VN [289], we observed that reduced mean vascular density and 
improved pericyte-VEC interaction in the TME are biologic correlates associated with 
therapeutic vaccination against DLK1/DLK2 in tumor-bearing mice.  
In order for cancer vaccines to work effectively, effector T cells must extravasate through 
the tumor blood vessel wall and into the interstitial space in order to interact with antigen-
presenting stromal cell or tumor cell targets. However, conditions within the TME may suppress 
VEC expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and 
VCAM1, that may limit tumor infiltration by circulating (anti-tumor) T cells [320]. This 
situation may be remedied by combined administration of anti-angiogenic agents (such as the 
TKIs axitinib, dasatinib or sunitinib) along with a tumor-specific vaccine [206, 207, 321]. Our 
DLK1/DLK2-targeted vaccine has an advantage over conventional TAA-targeted vaccine due to 
the proximal accessibility of circulating T effector cells to tumor-associated vascular pericyte 
targets in contrast to tumor cells that require T cells to enter, transmigrate and functionally 
persist within the TME to mediate meaningful therapeutic action. Furthermore, our vaccine 
promotes sustainable immune-mediated VN that would be envisioned to improve the 
deliverability of co-delivered chemotherapies or adoptively-transferred (TCR- or CAR-
engineered) T cells, theoretically without invoking the development of drug resistance or the 
adverse side-effects associated with anti-VEGF monoclonal antibodies and TKIs. However, it is 
possible that low-doses of anti-angiogenic drugs, such as sunitinib, might further reduce 
immunoregulatory cell populations in support of an even more robust pro-inflammatory TME 
when combined with DLK1/DLK2-targeted vaccines [322].   
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When taken in the context to existing paradigms for temporal cascades of T cell 
infiltration into the TME [323, 324], we would propose that the vaccine-induced DLK1- and 
DLK2-specific T cells might represent an initial wave of effector TILs that trim and promote the 
maturation of tumor-associated blood vessels, leading to VN. The normalized TME is conducive 
to DC maturation and the subsequent cross-priming of “second set” CD8+ T cell responses 
reactive against tumor-associated antigens acquired by DC within the TME [302, 325]. This 
effectively drives a broadening in the anti-tumor T cell repertoire based on an “epitope 
spreading” paradigm [325, 326], such as we observed in the case of DLK1/DLK2-based 
therapeutic vaccines leading to the development of anti-gp100 CD8+ T cell responses in the B16 
melanoma model (Figure 19).  
One of the anticipated problems with immunotherapy is the development of immune 
evasion mechanisms in the tumor that would lead to treatment resistance. Vaccines induce anti-
tumor protection by expanding the size and specificity of the tumor-specific T response, with 
superior vaccines also promoting TIL recruitment. However, chronic inflammation in the TME 
(mediated by T cells or NK cells) may lead to upregulated expression of immune checkpoint 
molecules such PD-L1 [311, 327, 328] in the tumor which can subvert or delete protective PD-1+ 
T effector cells. Consistent with this paradigm, we observed that effective vaccination against 
DLK1/DLK2 led to increased numbers of inflammatory (IFN-γ+) TIL and to upregulated PD-L1 
expression in the TME. While we did not discern any significant benefit to tumor-bearing mice 
upon treatment with anti-PD-L1 monotherapy, we observed that the addition of PD-L1 blockade 
to our DLK1/DLK2-based vaccine regimen resulted in improved Type-1 CD8+ T cell-mediated 
control of tumor growth vs. either monotherapy. Our data support a model in which PD1/PD-L1 
blockade and anti-vascular vaccines complement each other in their ability to promote, recruit 
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and sustain therapeutic anti-tumor immunity within the TME. However even this “optimized” 
treatment strategy did not achieve tumor regression, suggesting room for further translational 
improvement by combination with additional immune checkpoint antagonists (such as anti-
B7H3, anti-Gal9 or -Tim3, and anti-PD-L2 or -PD1) in extended treatment protocols, prior to the 
translation of such approaches into the clinic. 
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4.0  GENERAL DISCUSSION 
Due to its significant role in the proliferation and maintenance of tumor cells and its distinct 
physiological and molecular signature that distinguishes it from normal blood vessels, the tumor 
vasculature represents a promising target the generalized for immunotherapy of cancer. 
However, currently available treatments, such as anti-VEGF and TKIs that attack the tumor 
blood vessel and/or tumor angiogenesis are only transiently effective [158, 159, 259, 260]. 
Resistance to anti-angiogenic agents occurs when tumors activate alternative, compensatory 
pathways that can continue to support neovascularization and/or when tumor cells are 
reprogrammed so that they can invade deeper into normal tissue and co-opt the normal 
vasculature [299]. One possible approach to circumvent this problem is to induce immune-
targeting that preferentially eliminates “aberrant” tumor-associated vascular cells while sparing 
the vasculature in normal organs. Immunotherapy has the potential to provide long term control 
or even complete eradication of tumors due to its capacity to induce durable anti-tumor responses 
and memory cells [202, 203]. 
In this thesis, I present two novel antigens, DLK1 and DLK2, as targets for cancer 
therapeutic vaccines. DLK1 and DLK2 are preferentially expressed by tumor-associated 
pericytes in RENCA renal cell carcinomas growing s.c. in Balb/c mice but not in the animal-
matched tumor-uninvolved kidney vasculature (which serves to limit concerns for off-target 
pathologic effects). In Chapter 2, I show that immune-targeting of DLK1 via specific peptide- or 
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gene-based therapeutic vaccination in vivo resulted in immune-mediated reduction in RENCA 
tumor growth. However, tumors in DLK1-vaccinated animals ultimately progressed. I show in 
Chapter 3 that vaccine-induced removal of DLK1+ pericytes in the TME leads to a compensatory 
increase in DLK2 expression by tumor-associated vascular pericytes.  DLK1 and DLK2 are 
homologous members of the EGF-like protein family that regulate each other’s expression such 
that the forced downregulation of one gene product results in the upregulation of the other gene 
product and vice versa [251, 252]. I show that gene-based vaccination against both DLK1 and 
DLK2 provides superior anti-tumor therapeutic benefit when compared to vaccination against 
either single antigen alone as demonstrated by the tighter control of treated RENCA and B16 
tumor growth in vivo. Altogether, I’ve shown in this thesis that TBVA-targeted immunotherapy 
results in the activation of antigen-specific T cells, the actions of which lead to the inhibition of 
progressive tumor growth and to the reconditioning of the TME (i.e. vascular normalization, 
reduced hypoxia, reduced immunosuppressive cell populations and reduced CSC-like 
populations). 
There are several means to target TBVAs immunotherapeutically and in the studies 
described here, I employed peptide- and gene-based vaccination strategies to assess anti-TBVA 
immune-targeting in the RENCA tumor model. Our group has previously demonstrated that 
vaccine formulations composed of DCs that are engineered to express IL12 (DC.IL12) and then 
pulsed with MHC class I-presented peptides promote robust antigen-specific CD8+ T cells 
independent of CD4+ T cell help [197, 275]. As shown in Chapter 2, this formulation was 
successfully implemented using syngeneic DC.IL12 pulsed with DLK1-derived peptides 
(DC.IL12.pDLK1) to activate DLK1-specific CD8+ T cells.  I implemented a similar vaccine 
strategy to target tumor pericyte-associated antigen DLK2. Based on Immune Epitope Database 
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(http://www.iedb.org/) predictions, I picked MHC class I H-2d-restricted DLK2 peptide 
sequences that might be immunogenic, generated a DC.IL12 vaccine based on these peptides 
(DC.IL12.pDLK2), and injected naïve tumor-free Balb/c mice with the vaccine. Assessment of 
CD8+ splenocytes from the animals showed that some epitopes are putatively immunogenic 
(Appendix Figure 3a). However, application of the DC.IL12.pDLK2 vaccine in addition to 
DC.IL12.pDLK1 did not provide additional therapeutic benefits in RENCA-bearing Balb/c mice 
(Appendix Figure 3b). I suspect that the DLK2 peptide epitopes chosen may have been only 
weakly immunogenic and unable to induce a discernable immune response or that while 
immunogenic as synthetic sequences, these peptides were only inefficiently processed and 
presented in tumor MHC I complexes naturally. Therefore, in order to develop a more universal 
platform that would include all possible natural epitopes, I generated cDNA-based vaccines that 
would virally deliver the full-length gene product into host antigen presenting cells (APC), 
utilize the host APC’s gene expression and antigen presentation machineries, and lead to the 
cross-priming of more comprehensive DLK1- and DLK2-specific T cell repertoires. For this 
platform, I utilized a lentivirus system, as it has been shown that cutaneous injection with 
lentivirus results in the transduction and activation of skin-derived DEC205+CD8-/lo (cross-
priming) DCs [277]. For instance, cutaneous immunization of lentivirus recombinant for 
ovalbumin in mice led to the transport of transduced, OVA antigen-presenting skin-derived DCs 
to the vaccine site-draining lymph nodes where it was gound to stimulate Ag-specific CD8+ T 
cells capable of inhibiting the growth of OVA-expressing melanoma cells (i.e. B16.OVA) in 
vivo. 
Both DC.IL12.pDLK1 and lvDLK1 vaccines induced antigen-specific CD8+ effector T 
cells that targeted and eradicated DLK1+ pericytes, resulting in the remodeling of the tumor 
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vasculature in the RENCA tumor model. The remodeled tumor vasculature has a more mature 
phenotype: the immature microvessels are pruned, the VECs and pericytes in remaining vessels 
are more closely associated with the VECs, and the vessels are less leaky. All these vascular 
changes are associated with a decrease in hypoxia within the TME. I hypothesize that the shift 
from a hypoxic TME to a more normoxic condition may be one of the major factors for the 
preferential expression of DLK2 over DLK1 in the pericytes after treatment. DLK1 expression is 
controlled by hypoxia-related transcription factor HIF-1α [245] while DLK2 expression is 
controlled by the transcription factors Sp1 and KLF4 [313, 314], which are more active under 
normoxic environments [315, 316].  
Immunization of RENCA-bearing Balb/c mice and B16-bearing C57BL/6 mice with 
DLK1- and DLK2-targeted vaccines led to the coordinate activation of both DLK1- and DLK2-
specific CD8+ T cells. I postulate that the activation of a broader anti-TBVA T cell repertoire and 
the removal of both DLK1+ and DLK2+ pericytes (via T cell-mediated cytolysis or promotion of 
pericyte maturation and loss of DLK1/2 expression) would result in sustainable VN. In this 
context, I have presented data n support of the conclusion that lvDLK1 and lvDLK2 vaccination 
alleviates hypoxia, which is one of the important cues for pro-tumor angiogenesis in the TME 
[23]. Corollary to this is the downregulation of pro-angiogenic receptors, which also represent 
hypoxia-responsive gene products. These findings suggest that the TBVA-targeted vaccines not 
only induce VN but also inhibits a rebound in further formation of aberrant neovessels in treated 
animals. Furthermore, preliminary investigation of the TIL phenotype in B16 tumors suggests 
that there is an increase in central memory (TCM)-like CD8+ T cell population in animals treated 
with combined DLK1/DLK2 vaccine (Appendix Figure 4). In this regard, Restifo et. al. have 
previously shown that tumor infiltrating gp100-specific TCM cells, which have greater 
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proliferative capacity and ability to persist in the TME, promote a significant delay in B16 tumor 
growth in vivo when compared to adoptively-transferred effector memory T cells [329]. The 
(TCM)-like CD8+ T cells I observed prospectively provide a durable anti-DLK1/DLK2 activity 
that presumably underlies sustained VN in my tumor models.  
I would propose the following comprehensive mechanism by which the DLK1/DLK2-
targeted vaccines may effectively regulate tumor progression in vivo: first, the vaccine elicits 
anti-DLK1 and anti-DLK2 CD8+ T cells that preferentially react with DLK1+/DLK2+ pericytes in 
the TME, resulting in the significant ablation and remodeling (i.e. trimming) of the tumor-
associated vasculature and VN. Second, the increased pericyte coverage on VECs post-
vaccination limits leakage of plasma nutrients deep into the tumor and without these nutrients, 
tumor cells that are not adjacent (within 50-60 microns) to the vasculature undergo apoptosis. 
Such apoptotic tumor cells become a source of antigenic determinants that may subsequently be 
taken up by APCs recruited into the therapeutically “normalized” TME via stromal cell/VEC-
produced chemokines. Lastly, the activated APCs may then cross-prime a “second wave” of 
protective T cells that are broadly reactive against both TBVAs and TAAs [325], effectively 
expanding the protective anti-tumor T cell repertoire based on an “epitope spreading” paradigm 
[325, 326]. Indeed, I report that such is the case in DLK1/DLK2-based therapeutic vaccines, 
where I also observed therapy-associated induction of anti-gp100 CD8+ T cell responses in the 
B16 melanoma model. Treatment-linked upregulation of CXCL10 and VCAM1 expression in 
the remodeled tumor stroma promote the recruitment of this “second wave” of T cells into the 
tumor bed. 
The priming of naïve T cells classically occurs in secondary lymphoid organs (SLO), 
however, some recent evidence suggests that it can also occur within the tumor in extra-nodal 
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structures termed as tertiary lymphoid organs (TLO; [330, 331]). The formation of TLOs in the 
tumor lesion may be promoted by Type-1 proinflammatory DCs (Tbet+ DC) that recruit natural 
killer cells, B cells, and naïve T cells into the TME [330]. These recruited naïve T cells 
encounter their cognate antigen for the first time and develop into antigen-specific T effector 
cells within the TME. One of the features of TLO formation is the presence of high endothelial 
venules (HEV), which are generated only after the initial recruitment of the immune cells 
producing lymphotoxins or TNFα that serve as so-called TLO “initiator cells” [331]. Although I 
have not comprehensively investigated TLO within the therapeutic TME, my preliminary 
immunofluorescence data show that TBVA-targeted vaccination promotes the development of 
HEV-like structures in vivo i.e. DLK1-vaccinated RENCAs exhibit increased number of PNAd+ 
VEC in the TME when compared to tumors in the control treatment cohort (Appendix Figure 
5). Hence, I would infer that the initial wave of anti-DLK1 and anti-DLK2 TILs may be cross-
primed in the draining lymph node of the site of vaccine injection while the “second wave” of 
TILs that respond to a broader range of antigens may be cross-primed in either secondary 
lymphoid organs or in TLOs within the TME. This hypothesis will need to be investigated by 
others using informative models lacking SLO or in which SLO or TLO may be differentially 
perturbed. 
Another therapeutic effect of the DLK1/DLK2 vaccine is the reduction of tumor-
promoting cell populations, such as CSC-like cells (CD44+, CD133+, and Jarid1B+ cells [283-
285]) and regulatory immune cells (MDSC and Tregs) in the TME. This could reflect the ability 
of the vaccine-induced TILs to recondition the TME such that the recruitment, accumulation 
and/or expansion of these CSCs and regulatory immune cells are inhibited. For instance, in some 
types of tumors, the perivascular region provides a niche for CSCs wherein VECs provide 
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soluble factors that support CSC self-renewal [132-137, 281]. Therapeutic VN could potentially 
abrogate these CSC niches and disrupt cues for CSC maintenance. The observed decrease in 
hypoxia in the TME post-therapy may also suppress signals required for the 
survival/maintenance of tumor-initiating cells. Reduction in the expression of HIFs in the TME 
could lead to the transcriptional silencing of hypoxia-responsive stem cell-associated gene 
produces [283-285], in the disruption of the function of MDSCs [308], and in the inhibition of 
the generation and accumulation of Tregs [111].  Our data support a model wherein TBVA 
immunotherapy has multi-faceted effects in the TME – it induces effector cells to abolish 
abnormal vascular cells (and tumor cells via epitope spreading), reconditions the tumor stroma, 
and mitigates immune suppression.  
Notch signaling is critical in the resolution of physiological angiogenesis and maturation 
of the newly-formed blood vessels [20]. In tumors, blockade of Notch signaling via obstruction 
of DLL4-Notch1 interactions has been demonstrated to instigate the formation of excessive 
immature blood vessel branches as a result of uncontrolled endothelial proliferation [229, 230]. 
The role of DLK1 and DLK2 in angiogenesis and in the vasculature is largely unknown but the 
data presented in this thesis suggest that these members of the EGF-like family of proteins 
contribute significantly to the pathologic characteristics of the tumor vasculature by inhibiting 
Notch1 signaling. Vaccine-induced removal of DLK1+ and DLK2+ pericytes in the TME is 
correlated with the upregulation of Notch signaling elements, notably the activation of NICD and 
the expression of Hes1 in tumor perivascular regions. Furthermore, Wnt signaling also appears to 
be activated in the vaccinated TME as indicated by the increased expression Frzd2, Frzd4 and 
Frzd7 transcripts [290]. As such, DLK1 and DLK2 inhibition in the tumor vasculature may 
reinforce Notch/Wnt signaling to negatively regulate tumor-associated angiogenesis, consistent 
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with the proposed model in which activation of the Wnt/β-catenin/Notch signaling pathways in 
tumor endothelia leads to VN [289]. The collaboration between DLK1/DLK2 vaccine and 
Wnt/β-catenin/Notch signaling axis in the anti-tumor response needs to be further elucidated in 
future studies. My data suggest that Notch signaling plays a role in the therapeutic activity of 
DLK1/DLK2 vaccine based on the partial ablation of tumor growth control when a 
pharmacological Notch antagonist (i.e. DAPT) was combined with the vaccine protocol.  
Although coordinate targeting of both DLK1 and DLK2 led to a decrease in 
immunosuppressive cell populations, immune evasion by the tumor is still possible through other 
means. For instance the generation of IFNγ by TILs contributes of high levels of PD-L1 in 
tumors, providing the tumors a mechanism to develop adaptive resistance to the evolving anti-
tumor immune response [311, 328]. This means that vaccine-induced effector cells may 
successfully infiltrate the tumor via the vaccine-normalized vasculature only to be deleted or 
subverted by the PD-L1 signals contributed by tumor cells or stromal cells within the TME.  
Thus, the application of immune checkpoint inhibitors may augment the activity of the vaccine-
induced T cells. Indeed, application of PD-L1 blocking antibodies in addition to DLK1/DLK2-
targeted vaccine resulted in improved Type-1 CD8+ T cell-mediated control of tumor growth 
when compared to either monotherapy. This demonstrates that the complementary action of 
PD1/PD-L1 blockade and anti-vascular vaccines may sustain the anti-tumor activity of 
immunotherapy-induced TIL in our tumor models. 
In conclusion, the immune targeting of pericyte-associated antigens DLK1 and DLK2 is 
therapeutic in RENCA and B16 tumor models. The combination of DLK1- and DLK2-targeted 
vaccine generates potent effector T cells that remodel the tumor stroma, contributing to further 
anti-tumor effects. I also show that this TBVA-targeted therapeutic regimen is amenable to 
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complementation using immune checkpoint blockade, thus defining an innovative treatment 
strategy applicable to a broad range of solid cancers.  
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5.0  FUTURE DIRECTIONS 
5.1 ELUCIDATION OF THE ROLE OF NOTCH IN THE THERAPEUTIC IMMUNE 
RESPONSE INDUCED BY DLK1/DLK2 IMMUNE TARGETING 
Although I have shown that vaccine-induced VN is associated with the activation of Notch 
signaling, the exact role of Notch in the therapeutic efficacy of the vaccine remains unknown. 
Dependency of the vaccine on Notch signaling to generate anti-tumor responses was partially 
demonstrated when inhibitor DAPT was shown to diminish the anti-tumor efficacy of the DLK1-
based vaccines. However, γ-secretase inhibitors applied systematically suppress Notch signaling 
not only in the tumor vasculature but in other tissue compartments as well. Hence, to precisely 
define the consequence Notch activation on DLK1/DLK2 vaccine, conditional mouse knockout 
models could be generated in which Notch signaling is only deficient in VECs or pericytes (or 
only under conditions of hypoxia in the TME). 
In addition to the VECs, I also observed that Hes1 expression was also enhanced in other 
cells in the perivascular region after therapeutic vaccination against DLK1/DLK2. The 
identification/characterization of these Hes1+ cells would contribute to a better understanding to 
the therapeutic mechanism of action associated with these vaccines and the suitability of 
combining DLK1/DLK2 vaccination with other anti-cancer agents, especially those that are 
involved in Notch modulation. These Hes1+ stromal cells may include immune cells, such as 
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DCs and T cells that are known to be regulated by Notch signaling. Indeed, Notch activation has 
been implicated in the maturation and activation of DCs, as well as, in the differential secretion 
of cytokines and chemokines by DC subsets [293, 332]. In T cells, Notch inhibition has been 
shown to decrease CD4+ and CD8+ cell proliferation, NF-κB activity, and IFN-γ production in 
peripheral T cells [333]. 
5.2 COMBINATION OF DLK1/DLK2 VACCINE WITH OTHER ANTI-TUMOR 
THERAPIES 
The abnormal tumor-associated blood vasculature results in spatial and temporal heterogeneity in 
blood perfusion, limiting the access of drugs and effector immune cells to poorly perfused 
regions of the tumor [88, 90, 140, 334]. Immune targeting of DLK1+ and DLK2+ pericytes could 
improve the delivery and efficacy of chemotherapies and other immunotherapies by promoting 
VN. The vaccine-induced VN could restore fluid pressure gradients that would allow uniform 
flow-driven penetration of chemotherapeutic agents into the tumor [334]. Furthermore, increased 
oxygenation in the TME could contribute to the efficacy of chemotherapy. The DLK1/DLK2 
vaccine could improve other immune-based therapies (such as ACT and TAA-based vaccines) 
by enhancing effector cell extravasation and by alleviating immunosuppression in the TME. 
Conventional anti-angiogenic drugs only normalize the vasculature transiently, signifying that 
there is only a limited window of time during which they may assist the delivery of 
chemo/immune-therapeutic agents into the TME. TBVA-targeted vaccines may provide more 
durable VN in the TME, however, particularly in the context of combination regimens, collateral 
toxicities (such as autoimmune pathology resulting from specific vaccine targeting or as a 
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consequence of “epitope spreading” in the therapeutic T cell repertoire) will need to be carefully 
investigated/monitored. 
The activity of the DLK1/DLK2 vaccine could be improved through combination with 
TKIs and immune checkpoint inhibitors. TKIs such as sunitinib have been shown to have 
immunogenic modulating capabilities that could synergize with the DLK1/DLK2 anti-tumor 
activity [208, 335]. TKIs could reduce immunosuppressive cell populations, promote a pro-
inflammatory TME, and induce phenotypic changes in the tumor cells that would make them 
more susceptible to T cell killing (i.e. T cells activated after vaccination via epitope spreading 
mechanisms). Development of adaptive immune evasion is one of the hurdles of immunotherapy 
[309, 310]. As presented in Chapter 3, PD-L1 blockade augmented the therapeutic efficacy of 
DLK1/DLK2-targeted vaccination but only to a degree, indicating that other molecules and 
pathways may participate to underlie tumor evasion of vaccine-induced effector T cells. 
Inclusion of other checkpoint inhibitors such as anti-CTLA-4, anti-Tim3, and anti-Lag3 should 
be considered for inclusion in combination vaccines in order to promote and sustain more robust 
anti-tumor T cell activity in vivo. 
5.3 ADDITION OF OTHER TBVA IN THE DLK1/DLK2 VACCINE 
FORMULATION 
Although I infer that the DLK1/DLK2 vaccine could provide a durable anti-tumor response, 
resistance to the vaccine is always a possibility. In particular, the therapeutic TME (after 
vaccination against DLK1/DLK2) should be investigated for expression of alternate gene 
products postulated to serve as NOTCH antagonists. If such targets are preferentially expressed 
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in the TME and not in normal somatic tissues, they should be considered for inclusion in 
prospective interventional approaches. As with anti-angiogenic drugs, the tumor could also 
utilize alternative pathways to compensate for the loss of DLK1 and DLK2 in the tumor 
vasculature. An anti-vascular vaccine that includes a broader range of VEC-associated and 
pericyte-associated antigens (i.e. EphA2, HBB, NRP-1, PDGFRβ, TEM1, VEGFR1, and 
VEGFR2 [197] in addition to DLK1 and DLK2) could avert vaccine resistance. Novel TBVAs 
should also be identified and investigated for the suitability as cancer vaccine targets. 
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6.0  APPENDIX 
 
Appendix Figure 1. DLK1 is differentially expressed by human RCC-associated pericytes. 
(a) Freshly-harvested RCC tumor and patient-matched normal adjacent kidney tissues (NAT) were mechanically 
and enzymatically digested into single-cell suspension and sorted by flow cytometry based on forward scatter and 
side scatter, DAPI exclusion (to exclude dead cells), a CD56negCD45neg phenotype, and then selectively into 
CD146+CD34neg pericytes and CD146+CD34+ VEC populations. (b) mRNA was isolated from sorted pericytes and 
VEC from NAT and RCC tumor and analyzed for DLK1 expression by real-time PCR. Relative mRNA expression 
was normalized to housekeeping HPRT1 transcript expression. (c) RCC tumor and NAT sections were analyzed for 
expression of DLK1 (red) by immunofluorescence microscopy. Mean fluorescence intensity +/- SD was quantitated 
from 3 independent fields per slide as described in Materials and Methods. Data are representative those obtained in 
3 independent experiments performed. *p < 0.05 (t-Test). 
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Appendix Figure 2. Activation of Notch signaling in RENCA treated with lvDLK1 + lvDLK2 vaccine. 
Tumors harvested from day 21 RENCA-bearing mice receiving the indicated vaccines were sectioned and assessed 
for VECs (red) and for expression of the cleaved intracellular domain of Notch1 (NICD, green) in (A), or for VECs 
(green) and for expression of the NOTCH down-stream target Hes1 (red) in (B) by fluorescence microscopy as 
described in Materials and Methods. Scale bar = 1mm. All data are representative of those obtained in 3 independent 
experiments. 
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Appendix Figure 3. Immunization with peptide-based DLK2 vaccine is not therapeutic even in combination 
with DLK1 peptide-based vaccine. 
(a) SYFPEITHI and IEDB were utilized to predict DLK2 epitopes and high scoring peptides were synthesized as 
described in [197]. Balb/c DCs ectopically expressing IL12 (as described in Chapter 3) were pulsed with equimolar 
(10mM) mixture of DLK2 peptides. These pools of peptide-based vaccines were used to immunize naïve Balb/c 
mice (as described in Chapters 2 and 3) twice, with each injection being 1 week apart. Spleens were harvested from 
the mice 7 days after the second immunization. Splenocytes were stimulated with individual peptides (as described 
in Chapter 3) and IFN-γ production was measured by ELISA. (b) RENCA-bearing Balb/c mice were vaccinated 
with DC.IL12 that had been pre-loaded with DLK1 peptides, DLK2 peptides or combination of both on Days 10 and 
17 post-tumor inoculation. Tumor growth was monitored longitudinally and is reported as the mean ± SEM for 5 
animals per group. * P < 0.05, representative of 2 experiments. 
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Appendix Figure 4. Characterization of memory TILs in DLK/DLK2-treated B16 tumors. 
Day 20 tumors from animal cohorts in Figure 17 were harvested and digested into single cell suspensions as 
described in the Chapter 3.3.5. The CD44+ TEM and CD44+ CD62L+ TCM CD3+CD8+ TIL populations were 
identified via flow cytometry. 
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Appendix Figure 5. Formation of HEV-like structures in the DLK1-immune targeted RENCA TME. 
Tumor sections from untreated and DC.IL12- and DC.IL12.pDLK1- vaccinated RENCA (Figure 15) were 
immunostained for CD11c (eBioscience), CD3 (BD Pharmingen), and PNAd (BD Pharmingen). PNAd+ structures 
were counted per 200x view field. *P < 0.05 
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